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ABSTRACT 
Background: Uterine cervical cancer affects women of all ages and has a 
generally favorable prognosis. Many survivors live long with the consequences 
of the disease and its treatment, and therefore it is important to characterize 
potential treatment-induced morbidity. 
Aims: To investigate different hormonal aspects and work loss among cervical 
cancer survivors, by treatment modality.  
Methods: In a pilot study, we analyzed serum levels of anti-Müllerian hormone 
(AMH) and follicle-stimulating hormone (FSH) as measurements of ovarian 
function, as well as estradiol and androgens in serum, and assessed sexual 
function before and after treatments in a one-year cohort of cervical cancer 
patients (N = 71). We also used Swedish national registers to investigate use of 
hormone therapy after cervical cancer treatment, and lost workdays due to sick 
leave and disability pension among 837 and 1971 patients, respectively.  
Results: Serum levels of AMH were undetectable one year after salpingo-
oophorectomy or radiotherapy among patients < 45 years of age at diagnosis. 
After radical hysterectomy and pelvic lymphadenectomy with ovarian 
preservation, AMH declined, whereas no change was found in serum levels of 
FSH. Circulating levels of total and free testosterone decreased after pelvic 
radiotherapy among pre- as well as postmenopausal women. No correlations 
were found between androgen levels and female sexual function index (FSFI) 
scores following treatment. Among women with estrogen deprivation due to 
salpingo-oophorectomy or radiotherapy, 67% had at least one dispensing of 
hormone therapy during the period 0.5 to 1 year after diagnosis, and 46% 
dispensed at least 75% of the recommended dose. The proportion of users 
decreased during follow-up. Relapse-free cervical cancer patients had more 
lost workdays than matched comparators from the general population for 4 
years following diagnosis, and were at increased risk of disability pension 
following hysterectomy or chemo/radiotherapy. Women treated with fertility-
sparing surgery did not have more lost workdays than the comparators beyond 
the first year and were not at increased risk of disability pension.  
Conclusions: Serum levels of AMH were reduced after radical hysterectomy 
with ovarian preservation, indicating a possible risk of early ovarian failure. 
Testosterone in serum was reduced after radiotherapy, but was not associated 
with sexual function in this pilot setting. Less than half of cervical cancer 
survivors likely to have therapy-induced early menopause used hormone 
therapy at, or close to, the recommended dose, and the use decreased during 
follow-up. All treatment modalities for cervical cancer except fertility-sparing 
surgery were associated with long-term work disability.  
 
MeSH terms: uterine cervical cancer; anti-Müllerian hormone; hysterectomy; 
androgens; testosterone; sexual dysfunction; hormone replacement therapy; 
premature menopause; radiotherapy; oophorectomy; sick leave 
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INTRODUCTION 
 
Cancer survivorship issues are becoming increasingly important, due to a 
general increase in cancer incidence [1] and an improved cancer survival [2]. 
Uterine cervical cancer has a favorable prognosis, especially at younger ages 
[3], and therefore many patients will have a long life expectancy after 
treatment. The overall aim of this thesis was to examine side effects of 
treatments among cured patients. About half of all women diagnosed with 
cervical cancer are under 50 years of age, and for these women, treatment 
often leads to permanent loss of fertility and early menopause. Therefore, 
hormonal aspects are of special concern in this patient group. The majority of 
the women diagnosed with cervical cancer are also in their working ages, and 
the ability to work following cancer diagnosis and treatment is an important 
part of the restoration to health.  
The background chapter gives an introduction to cervical cancer and its 
treatment and the regulation and importance of sex hormones in women. It 
also presents a summary of what is known, and not known, about treatment 
effects on hormone levels, and the possible consequences of reduced 
hormone levels. Recommendations for the use of hormone therapy in 
general, and after cervical cancer are described. The chapter also includes a 
short overview of morbidity and patient-reported distressful symptoms after 
treatment, which may have implications for quality of life as well as long-term 
work ability in cervical cancer patients. Finally, studies evaluating work loss 
among cancer patients in general, and among gynecologic or cervical cancer 
survivors in particular, are summarized.  
The four studies in the thesis aim to investigate hormonal changes during the 
first year following diagnosis and treatment (studies I and II), use of hormone 
therapy among women in therapy-induced early menopause (study III) and 
work loss (study IV) among survivors. 
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BACKGROUND 
 
UTERINE CERVICAL CANCER 
 
Incidence 
In 2012, uterine cervical cancer was the 4th most common cancer among 
women worldwide, with an absolute majority of cases and deaths in low-income 
countries (Figure 1) [4]. In high-income countries, incidence and mortality from 
cervical cancer have decreased over the past decades following the 
introduction of screening programs [5].  In Sweden, cytologic screening was 
introduced successively starting in 1964, and has led to increased survival 
rates, probably due to an earlier detection [6, 7]. The annual incidence has 
declined from 25 cases/100,000 person years in 1965 to 8.4/100,000 person 
years in 2012 [8]. In 2013, 468 women were diagnosed with cervical cancer, 
of which 56% were under 50 years and 36% under 40 years [9].  
 
 
 
 
 
Figure 1. Estimated cancer incidence and mortality in women in more developed regions 
(Europe, North America, Australia/New Zeeland, Japan) and less developed regions (Africa, 
Asia excluding Japan, Latin America, The Caribbean, Melanesia, Micronesia, Polynesia) of 
the world in 2012. From Ferlay et al. 2014 [4] with permission. 
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Symptoms and spread 
The cervix is anatomically defined as the lower third of the uterus. Cancer 
originates from the vaginal surface or the canal [10], but usually starts in the 
metaplastic epithelium of the cervical transformation zone, where the 
squamous epithelium of the ectocervix replaces the columnar epithelium of 
the endocervix (squamo-columnar junction) [11]. Early cancers can go without 
symptoms, but coital or stress bleeding and discharge is common. Weight 
loss and pain are signs of advanced tumor stages [12]. Untreated cervical 
tumors grow in continuity into the paracervical tissues and pelvic organs, 
spread to regional lymph nodes (parametrial, obturator, internal iliac, external 
iliac, presacral, common iliac) and metastasize to distant organs (aortic and 
mediastinal lymph nodes, lungs, and skeleton)[10]. 
 
Histopathology  
Almost all cervical tumors are of epithelial origin and can roughly be divided 
into squamous cell cancer (80%) and adenocarcinoma (20%) [13]. Squamous 
cell cancer can be further classified into keratinizing, non-keratinizing, basaloid, 
verrucous, warty, papillary, lymphoepithelioma-like, and squamotransitional 
subtypes. Adenocarcinomas are sub-divided into mucinous, endometroid, clear 
cell, serous and mesonephric subtypes [14]. Over the past 50 years there has 
been an increase in the relative proportion of adenocarcinoma in Sweden [15]. 
One suggested explanation is that the current screening methods are less 
effective in discovering adenocarcinoma as compared to squamous cell cancer 
[15]. More unusual tumors are, for instance, glassy cell carcinoma and 
neuroendocrine (small cell) carcinoma, which have a worse prognosis than 
other histological subtypes [16, 17].  
 
Etiology 
Human papilloma virus (HPV) is considered the causal factor for cervical 
cancer [18]. HPV is found in practically all cases of squamous cell carcinoma 
and adenocarcinoma [18, 19], with the exception of rare subtypes such as 
gastric, mesonephric adenocarcinoma and clear cell carcinoma [20-22]. The 
association between HPV and cervical cancer was first noted by the German 
virologist Harold zur Hausen in the 1970s [23], and he was rewarded the 
Nobel Prize in 2008 for this discovery.  
HPV types are divided into low- and high cancer risk types, since they exhibit 
different disease-causing characteristics. Fifteen HPV types are classified as 
high risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 [24]. 
HPV infection is considered “necessary but not sufficient” [11] for the 
progression through the precancerous stages low and high grade 
intraepithelial lesion, (previously called cervical intraepithelial neoplasia, CIN, 
1, 2 and 3) to invasive cancer, but the exact co-factors necessary for the 
malignant transformation are not known. There is also considerable 
spontaneous healing of both HPV infection and precancerous lesions [25]. 
  
	   Background	   	  	   	  
13 
Long before the discovery of HPV, it was noted that cervical cancer was 
mainly diagnosed in younger women with many children, whereas 
endometrial cancer was diagnosed later in life in childless women [26]. 
Reproductive and other factors have, since then, been further evaluated in 
detail. In a meta-analysis from 2007 with data from 12 epidemiological 
studies, the risk of cervical cancer increased with the number of full-term 
pregnancies, the number of sexual partners, low age at first intercourse, low 
age at first birth, use of oral contraceptives, and smoking (Table 1) [27].   
 
 
Table 1. Risk factors for squamous cell carcinoma and adenocarcinoma versus cervical 
cancer free controls. Relative risks (RR) were stratified by study, age at diagnosis, number of 
sexual partners, age at first intercourse, number of full-term pregnancies, smoking status, 
previous Pap smear (yes/no), and duration of oral contraceptive use. Bold numbers are 
significantly different between cancer patients and controls. Extracted from Table 2, 
International Collaboration of Epidemiological Studies of Cervical Cancer, 2007 [27], with 
permission.  
 
 Squamous cell 
carcinoma vs cancer-free 
controls 
Adenocarcinoma vs 
cancer-free controls 
  RR (95% CI) RR (95% CI) 
Number of full-term pregnancies   
 Nulliparous 0.69 (0.60–0.78) 0.94 (0.74–1.18) 
 1-2 1.00 (0.94–1.07) 1.00 (0.89–1.13) 
 3-4 1.50 (1.43–1.59) 1.36 (1.22–1.52) 
 5+ 2.08 (1.95–2.23) 1.61 (1.37–1.90) 
Number of sexual partners   
 1 1.00 (0.94–1.06) 1.00 (0.88–1.14) 
 2-5 2.00 (1.91–2.09) 1.63 (1.47–1.80) 
 6+ 2.98 (2.62–3.40) 2.64 (2.07–3.36) 
Age at first intercourse   
 21+ 1.00 (0.93–1.07) 1.00 (0.86–1.16) 
 18-20 1.60 (1.51–1.68) 1.50 (1.35–1.67) 
 <18 2.24 (2.11–2.38) 2.06 (1.83–2.33) 
Age at first birth   
 Nulliparous 0.85 (0.75–0.97) 1.14 (0.91–1.44) 
 25+ 1.00 (0.93–1.08) 1.00 (0.86–1.16) 
 20-24 1.66 (1.57–1.74) 1.44 (1.30–1.60) 
 17-19 2.16 (2.03–2.30) 2.10 (1.84–2.40) 
 <17 2.72 (2.42–3.05) 2.01 (1.53–2.65) 
Duration of oral contraceptive use   
 Current users 1.08 (1.06–1.09) 1.07 (1.04–1.11) 
 2-9 years since stopping 1.03 (1.02–1.05) 1.03 (1.00–1.06) 
 10+ years since stopping 0.98 (0.96–1.00) 1.02 (0.97–1.07) 
Smoking   
 Never 1.00 (0.94–1.06) 1.00 (0.89–1.13) 
 Past 1.01 (0.91–1.14) 0.74 (0.60–0.92) 
 Current 1.50 (1.38–1.63) 0.86 (0.73–1.01) 
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Female sex hormones have been suggested as risk factors for cervical 
cancer, due to the observed associations with reproduction, use of 
contraceptives and cervical cancer [27]. Studies have also suggested an 
association between an increased risk of cervical adenocarcinoma and 
postmenopausal hormone therapy (HT) [28, 29]. Association between sex 
hormones and cervical cancer has been supported by cell-line experiments, 
where both estrogen and progesterone promoted cervical cancer cell 
proliferation, which in turn made the cells vulnerable to mutations [30]. Apart 
from direct cellular effects, a potential biological explanation for the 
association between sex hormones and cervical cancer, is that high levels of 
estrogen or progesterone/progestogen, either due to oral contraceptives or 
pregnancy, can cause ectopy at the squamo-columnal junction, making it 
more accessible to HPV-infection [31].  
 
Current smoking is associated with squamous cell carcinoma, but not 
adenocarcinoma [32]. Proposed mechanisms include local genotoxic effects 
on the cervical epithelium that stimulate carcinogenesis, or localized 
immunosuppression. Immunological factors are known to affect cancer 
progression in general, and patients with severe immunosuppression, either 
due to acquired immunodeficiency syndrome (AIDS) or to medication, as in 
the case of organ transplant recipients, have an increased risk of cervical 
cancer [33].  
However, the associations between cervical cancer and several of the risk 
factors mentioned above may be confounded. The use of contraceptives, 
smoking, multi-parity, early sexual debut, and numerous sexual partners may 
all be associated with a behavior that increases the risk of encountering a 
partner with HPV. Therefore, evaluation of independent risk factors for 
cervical cancer should ideally be restricted to HPV-positive women. 
Established risk factors for cervical cancer among HPV-positive women are: 
oral contraceptive use more than 5 years [34], current cigarette smoking [32], 
multi-parity (increasing risk with increasing number of children), age at first 
full-term pregnancy (increasing risk with decreasing age) [35] and co-infection 
with chlamydia trachomatis and herpes simplex [36]. 
Primary and secondary prevention 
Three HPV vaccines for the prevention of cervical cancer are approved for 
clinical use – Cervarix®, Gardasil®, and Gardasil 9®. All vaccines are aimed 
at HPV 16 and 18 for their predominant role in cancer development, and have 
shown protection against precancerous lesions [37-39]. Gardasil® also 
protects against HPV 6 and 11 infection, and Gardasil 9® against HPV 6, 11, 
31, 33, 45, 52, and 58 [39]. The Swedish National Board of Health and 
Welfare (NBHW) decided in 2008 that HPV vaccination should be included in 
the national vaccination program, and it is now offered to girls aged 10-12 
years. 
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The destruction of precancerous lesions is a secondary prevention of cervical 
cancer that has been used since the construction of the colposcope (a lighted 
binocular microscope used to magnify the view of the cervix) by Hinselman in 
1924 [26]. During the same decade, the cytologist Papanicolau discovered that 
after brushing the cervix and studying the smear under microscope, cancer 
precursor cells could be detected. His discoveries led to the gynecological 
mass screening programs that started in the 1960’s [40]. Vaginal cytology is 
still used today and referred to as Papanicolau or Pap smear. Swedish women 
are offered Pap smear between 23 and 60 (or 65) years of age. From 2010 
liquid-based cytology has been used, which also allows HPV-testing [41]. 
Cervical tumors in women above screening age are discovered at more 
advanced stages, why an extension of current cervical screening program 
beyond 65 years has been proposed [42]. 
 
Diagnosis and staging 
Staging of cervical cancer is based on clinical evaluation of the size of the 
tumor and its extension into and beyond the pelvis at the time of primary 
diagnosis. According to the International Federation of Gynecology and 
Obstetrics (FIGO) staging system (Table 2) [3, 43], clinical examination – 
preferably under anesthesia – including biopsy and the use of endoscopy and 
plain x-rays are permitted methods of staging. Other, more advanced 
examinations, such as Magnetic resonance imaging (MRI) or Positron 
emission tomography (PET) scans are encouraged but not mandatory, since 
they are not available in all countries. Findings from MRI or PET do not 
change the clinical stage [3, 43]. The American Joint Committee on Cancer 
TNM cancer staging system [44] is similar to the FIGO system. It classifies 
cervical cancer based on three factors: the extent of the tumor (T), cancer 
spread to lymph nodes (N), and cancer spread to distant sites (M), by findings 
from surgery or imaging (Table 2).  
 
In Sweden, women with cervical cancer are diagnosed by way of biopsy. The 
tumor staging is based on clinical examination under anesthesia, and typically 
the women do an MRI of the pelvis, and computed tomography (CT) of the 
thorax and abdomen. For tumors larger than 4 cm, or suspected growth 
beyond the cervix, PET-CT is usually also performed.  
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Table 2. The FIGO nomenclature [3, 43] and the TNM cancer staging system [44]. The FIGO 
staging system is the one used by gynecologists internationally.  
 
Primary tumor (T) 
TNM FIGO  
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ (preinvasive carcinoma) 
T1 I Cervical carcinoma confined to the cervix (disregard extension to the corpus) 
T1a IA Invasive carcinoma diagnosed only by microscopy; stromal invasion with a maximum 
depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 
7.0 mm or less 
T1a1 IA1 Measured stromal invasion ≤ 3.0 mm in depth and ≤ 7.0 mm in horizontal spread 
T1a2 IA2 Measured stromal invasion > 3.0 mm and ≤ 5.0 mm with a horizontal spread ≤ 7.0 mm 
T1b IB Clinically visible lesion confined to the cervix or microscopic lesion greater than 
T1a/IA2 
T1b1 IB1 Clinically visible lesion ≤ 4.0 cm in greatest dimension 
T1b2 IB2 Clinically visible lesion > 4.0 cm in greatest dimension 
T2 II Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of 
vagina 
T2a IIA Tumor without parametrial invasion 
T2a1 IIA1 Clinically visible lesion ≤ 4.0 cm in greatest dimension 
T2a2 IIA2 Clinically visible lesion > 4.0 cm in greatest dimension 
T2b IIB Tumor with parametrial invasion 
T3 III Tumor extends to pelvic wall and/or involves lower third of vagina and/or causes 
hydronephrosis or nonfunctional kidney 
T3a IIIA Tumor involves lower third of vagina, no extension to pelvic wall 
T3b IIIB Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctional kidney 
T4 IV Tumor invades mucosa of bladder or rectum and/or extends beyond true pelvis  
T4a IVA Tumor invades mucosa of bladder or rectum  
T4b IVB Tumor extends beyond true pelvis 
Regional lymph nodes (N) 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Regional lymph node metastasis 
Distant metastasis (M) 
M0  No distant metastasis 
M1  Distant metastasis (including peritoneal spread; involvement of supraclavicular, 
mediastinal, or paraaortic lymph nodes; and lung, liver, or bone) 
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Figure 2. Cervical cancer stages IA to IVB according to FIGO. From Quinn et al. [3], with 
permission. 
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Treatment recommendations 
Swedish cervical cancer treatment guidelines are developed by health 
professionals in collaboration with the six regional cancer centers. Treatment 
procedures differ only slightly between regions [41, 45-49]. National guidelines 
are under development. Cancer treatment can be surgical, oncological, or a 
combination, depending on stage and histopathology findings.  
 
Early stages 
 
For stage IA1 (micro-invasive cancer, only visible through microscopic 
evaluation of biopsy material) simple hysterectomy is recommended, and can 
be performed either abdominally or vaginally. Conization is an alternative if 
fertility is desired.  
 
For stage IA2 to IB1and IIA (from micro-invasive tumors with stromal invasion 
> 3 mm up to clinically visible tumors, but without parametrial invasion) radical 
hysterectomy and pelvic lymphadenectomy (due to the risk of lymph node 
metastases) is recommended. If fertility is desired, and tumor size is less than 
2 cm, radical trachelectomy plus laparoscopic lymphadenectomy can be 
performed. Radical vaginal trachelectomy, first described by the French 
gynecologist Dargent in 1986, consists of removal of the cervix, parametrial 
tissue and upper part of the vagina. The cervix is transected 1 cm above the 
tumor margin and only the vaginal branch of the uterine artery is ligated. A 
prophylactic cerclage is sometimes inserted with a non-resorbable stitch [50].  
 
The radical hysterectomy usually performed in Sweden - Piver type II [51] or 
Querleu/Morrow type B [52] - is based on the operative techniques first 
performed by Reis and Clark at Johns Hopkins Hospital in the mid 1890’s [53] 
and later developed by Wertheim (1912) and Meigs (1951) [54]. The purpose 
of the modified radical hysterectomy, as described in the article by Piver from 
1974 [51], is to remove paracervical tissue, but preserve blood supply to the 
distal ureters and bladder. The uterosacral ligaments are resected midway 
between the uterus and the sacral attachments, and the medial half of the 
cardinal ligament and the upper 1/3 of the vagina are removed. Pelvic 
lymphadenectomy is performed at the external iliac, internal iliac, common 
iliac and obturator fossa [52, 54]. Ovarian preservation is considered safe in 
early stages [55]. Studies on minimally-invasive surgery by means of 
laparoscopy-assisted radical hysterectomy (LAVH) [56] or robot-assisted 
laparoscopic hysterectomy (RAVH) [57, 58] indicate shorter length of hospital 
stay and time to normal daily activity for the patients compared with open 
surgery, however, due to the lack of randomized clinical trials, these methods 
are not yet recommended in general clinical practice [59]. The sentinel node 
technique may in the future reduce the use of total regional lymphadenectomy 
[60]. 
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When surgery is chosen as primary treatment, adjuvant radiotherapy plus 
chemotherapy is typically given in case of positive lymph nodes, growth in 
parametria or positive surgical margins, large tumor volume, capillary 
involvement or growth in the outer 1/3 of the cervical stroma [45, 61]. 
 
Advanced stages and recurrent disease 
 
For stages IB2, IIB, III, and IVA (locally advanced tumors with increasing 
degrees of parametrial invasion up to invasion of the vagina/ureters/bladder 
and rectum) standard primary treatment is external beam radiotherapy plus 
intracavitary radiotherapy (brachytherapy) with concurrent weekly cisplatin 
chemotherapy [62, 63]. A Nordic protocol for CT-based external beam 
radiotherapy in locally advanced cervical cancer – NOCECA – was initiated in 
1994 [64, 65]. The pelvic field for the external beam radiotherapy in NOCECA 
includes the internal and external iliac nodes and the lower common iliac nodes 
up to the level of the space between lumbar vertebrae L4 and L5. The 
treatment is delivered with a daily fraction of 1.8-2.0 Gray (Gy) over a period of 
5 to 6 weeks. The total external radiotherapy dose is 45-50 Gy to the adjuvant 
targets (lymph nodes) and 50-56 Gy to the tumor target, depending on the 
number of brachytherapy insertions (usually two to three are given). During 
later years the use of MRI for three-dimensional treatment planning has 
allowed more exact individual adaptation of dose to target organs (clinical 
target volume [66]), and has been shown to improve local control and reduce 
morbidity [67, 68]. Extended field radiation should be considered in patients 
with positive common iliac or aortic lymph nodes. 
 
Ovarian transposition before start of pelvic radiotherapy is an attempt to 
preserve ovarian function in younger women. The infundibulopelvic ligament 
including ovarian vessels is mobilized and each ovary is placed as high as 
possible with the least possible tension, preferably in the paracolic gutters 1.5 
cm above the iliac crest. Surgical clips are applied to the upper and lower 
borders of each transposed ovary, so their position can be identified on X-ray 
[69].  
 
Total pelvic exenteration can be performed in patients with recurrence after 
irradiation or with primary stage IV disease, if the tumor has advanced into the 
bladder and rectum but remains confined to the pelvis. The procedure 
involves en bloc resection of all pelvic structures. If the tumor grows only 
anteriorly, the rectum can be left intact by removing the bladder and uterus– 
anterior exenteration. Posteror exenteration means to remove the uterus and 
rectum but leaving the urinary bladder intact [70].  
 
For stage IVB (distant metastases) or recurrent disease the prognosis is poor 
[3]. Distant metastases can be treated with palliative chemotherapy, often 
cisplatin in combination with topotekan [71] or paclitaxel [72]. The response 
rate of chemotherapy is lower in patients with disease recurrence in a 
previously irradiated pelvis [73], due to disruption of the pelvic blood supply.  
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Prognostic factors 
The FIGO 26th annual report [3] identified several prognostic factors 
associated with overall survival in 11775 women from 37 countries treated 
1999-2001 (mean age 52 years). Stage was the most important independent 
prognostic factor. Patients with early tumors (stage IA1) had a 5-year survival 
of 98% compared to 9% for patients in stage IVB. The presence of lymph 
node metastases reduced 5-year survival to 64% compared to 92% for 
patients without lymph node metastases. In the multivariate analysis (Table 
3), age (≥50 versus <50 years) was associated with a worse outcome only in 
stage I disease. Squamous cell cancer was associated with a better outcome 
than adenocarcinoma. Tumor size and lymph node status were predictors of 
worse outcome primarily among patients diagnosed in stages I-II. 
 
 
Table 3. Multivariate analysis of patients treated in 1999-2001, adjusted for country and 
stratified by age, histological type, grade, tumor size, lymphovascular space involvement, and 
lymph node status. Extracted from table 12, Quinn et al., 2006 [3], with permission.  
 
                           Hazard ratio (95%CI) 
 Stage I Stage II Stage III Stage IV 
     
Age     
<50 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
>=50 1.4 (1.2−1.7) 1.0 (0.9−1.1) 1.0 (0.9−1.2) 1.0 (0.9−1.3) 
Histology     
Squamous cell 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Adenocarcinoma 1.9 (1.6−2.4) 1.4 (1.1−1.7) 1.5 (1.2−1.9) 1.5 (1.1−2.0) 
Tumor size     
<=4 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
>4 2.0 (1.5−2.8) 1.6 (1.4−1.8) 1.4 (1.2−1.7) 1.2 (0.9−1.6) 
Lymph node 
metastases 
    
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 3.8 (3.0−4.9) 2.4 (1.8−3.2) 1.5 (0.9−2.7) 1.4 (0.5−3.5) 
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SEX STEROID HORMONES IN WOMEN 
 
Regulation of sex steroid production 
Sex steroid hormones – estrogens, progesterone and androgens – are 
synthesized in the ovary and in the adrenal cortex, but can also be converted 
in peripheral tissues, such as fat tissue [74], muscles [75], and the liver [76].  
Hypothalamus is the central regulator of steroid hormone production through 
the hypothalamic-pituitary-ovarian (HPO) and hypothalamic-pituitary-adrenal 
axes.  
The ovarian cycle 
The HPO axis regulates the cyclic secretion of ovarian hormones during the 
ovarian/menstrual cycle. Gonadotropin releasing hormone (GnRH) from the 
hypothalamus stimulates the secretion of the gonadotropins luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. In turn, 
these gonadotropins control the secretion of sex steroid hormones from the 
ovaries [77]. 
 
During the early phase of the menstrual cycle (the follicular phase), circulating 
concentrations of FSH secreted by the pituitary gland increase and stimulate 
the growth and development of a group of follicles in the ovaries. Usually, only 
one of the follicles will be selected to fully mature and ultimately rupture at the 
time of ovulation. The growing follicle starts to produce estradiol and the 
peptide inhibin-B. In the ovulatory phase, the rise in estradiol and inhibin-B 
exerts positive feedback on LH secretion but inhibits FSH secretion from the 
pituitary. The LH surge stimulates the production of androgens and induces 
ovulation about 12 hours later. After ovulation, estradiol levels fall and the 
empty follicle in the ovary develops into the corpus luteum. During the later 
phase of the menstrual cycle (the luteal phase), the corpus luteum continues 
to produce estradiol and progesterone. In the absence of fertilization, the 
corpus luteum degenerates and the production of sex steroid hormones 
declines, which subsequently leads to the endometrial breakdown and 
menstruation [78]. 
The menopausal transition is the period in a woman’s life when cyclic 
secretion of female sex hormones from the ovaries disappears. In contrast, 
circulating levels of androgens (i.e. testosterone) decline as a consequence of 
age-related reductions in secretion by both the adrenal glands and the ovaries 
[79]. Menopause, the final cessation of menstruation, occurs when functioning 
ovarian follicles become depleted and the production of estradiol is too low to 
stimulate the endometrium to grow and then shed. As a consequence of low 
estradiol production, circulating levels of FSH from the pituitary will increase. 
Menopause is established by a marked elevation of FSH in the blood [78]. 
The median age of menopause is 51-52 years in the Western world [80-82]. 
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Ovarian sex steroid synthesis 
Ovarian sex steroid synthesis takes place in follicular theca and granulosa 
cells, but also in the ovarian stroma. Cholesterol is the major precursor, 
originating from circulating lipoproteins or de novo synthesis in the ovary [77]. 
According to the Armstrong-Dorrington ”two-cell theory” (Figure 3) [83], LH 
stimulates the theca cells to synthesize androgens. Androstenedione and 
testosterone diffuse into the granulosa cells, where FSH induces aromatase 
activity, and androgens are converted into estradiol, the major follicular product 
during the first half of the menstrual cycle. In late follicular phase, the granulosa 
cells of the corpus luteum are heavily vascularized, which allows cholesterol to 
enter directly. Cholesterol is converted to estradiol and progesterone, the major 
products of the corpus luteum during the second half of the menstrual cycle 
[77]. 
 
Figure 3. The “two-cell, two-gonadotropin theory” on ovarian steroidogenesis during the first 
half of the menstrual cycle. The pre-ovulatory follicle produces estradiol through a paracrine 
interaction between the theca and granulosa cells. In response to LH-stimulation, the theca 
cells convert cholesterol to androgens through several enzymatic steps. The granulosa cells 
do not have a direct connection to the circulation, but are dependent on diffusion of 
androgens (illustrated by androstenedione in the picture) from the theca cells as a substrate 
for estradiol aromatization. The aromatization is FSH-induced. Adapted from Schmidt [84], 
2011 (illustration by Jan Funke), with permission. 
  
Theca cell
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Anti-Müllerian hormone (AMH) 
Ovulation is not only regulated by the HPO-axis but also by a complex 
endocrine and paracrine signal-system of peptides [85] and growth factors in 
the oocyte, granulosa, theca, and stromal cells in the ovary [86]. A majority of 
these growth factors and signal molecules belong to the transforming growth 
factor (TGF-β) superfamily [87]. Anti-Müllerian hormone (AMH), previously 
called Müllerian inhibiting substance, is a dimeric glycoprotein [88] and a 
member of the TGF-β family. AMH is produced in the granulosa cells of the 
primary, pre-antral and small antral follicles (Figure 4) [89]. In these immature 
follicles, the paracrine activity of AMH inhibits FSH-stimulated follicle growth 
[78]. AMH concentration in these follicles remains high until the follicle reaches 
a diameter of about 8 mm, after which AMH production declines [90]. The 
decrease in AMH corresponds with the selection of a dominant follicle, which is 
characterized by the transition from low to high estradiol production [91]. AMH 
thereby regulates the development of the selected follicle that will undergo 
ovulation [92].  
 
 
 
 
Figure 4.  AMH is produced in early stages of follicle development (characterized by 
gonadotrophin-independent growth), as opposed to inhibin B and estradiol produced by 
follicles at later stages of development where growth is FSH-dependent. From Broer et al. 
[93], 2014, with permission.  
 
  
Schematic representation of follicle development emphasizing that AMH is produced in early 
stages of follicle development (characterized by gonadotrophin-independent growth), as 
opposed to Inhibin B and estradiol produced by follicles at later stages of development where 
growth is FSH-dependent. 
Simone L. Broer et al. Hum. Reprod. Update 
2014;20:688-701 
© The Author 2014. Published by Oxford University Press on behalf of the European Society of 
Human Reproduction and Embryology. All rights reserved. For Permissions, please email: 
journals.permissions@oup.com 
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Clinical use of AMH 
Since serum AMH mainly derives from antral follicles, and antral follicles 
indirectly represent the total number of primordial follicles [94], serum levels of 
AMH can be considered a measure of the ovarian reserve [93]. Serum AMH is 
relatively stable throughout the menstrual cycle [95] and correlates well with 
antral follicle count [96]. AMH is therefore a better test of the ovarian reserve 
than serum levels of FSH, estradiol or inhibin B [93]. Clinically, serum AMH 
has mostly been used to predict ovarian response to hyperstimulation during 
in-vitro fertilization [97]. AMH production peaks at an age of about 25 years. 
Thereafter, there is a steady decline to undetectable levels at an average age 
of 50–51 years, corresponding to the menopause [98]. Therefore, individual 
AMH-values may predict time to menopause [99-106]. Serum AMH can be 
affected by ethnicity, smoking, and body mass index (BMI), but the results are 
not consistent [93]. Serum levels of AMH have been found to be lower in oral 
contraceptive users [107-110].  
 
Measurement of AMH 
Serum AMH can be assessed by enzyme-linked immunosorbent assays 
(ELISA). In 2010, the AMH Gen II assay was introduced by Beckman-Coulter. 
This assay has a sensitivity of 0.08 µg/L and lower inter- and intra-assay 
coefficient of variation (< 5%) compared to other assays, as well as no cross-
reactivates to FSH, LH and inhibin [111]. However, the results may be 
affected by several other factors, for instance; pre-dilution, storage at -20°C 
for five days, and incubation at room temperature for seven days increased 
serum AMH concentrations [112]. Beckman-Coulter also issued a field safety 
notice warning that analysis of undiluted samples within 1-2 hours can 
generate higher values [113].  
Female androgen production  
In women, androgens are secreted by both the ovaries and by the adrenal 
glands. The major androgens produced in the ovary are androstenedione and 
testosterone. Androstenedione acts as a precursor for both estrogen and 
androgen synthesis and can be converted to testosterone and the more 
potent 5α-dihydrotestosterone (DHT) in the ovary [114] and in peripheral 
tissues (Figure 5) [115]. Testosterone and DHT are the two androgens that 
bind and activate the androgen receptor [77]. Since testosterone secretion is 
stimulated by LH, it has menstrual variation in fertile women, with a peak 
during the mid-cycle LH-surge [114]. Testosterone also displays circadian 
variation with peak levels in the early morning hours [79]. 
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The adrenal gland produces dehydroepiandrosterone sulphate (DHEAS), 
dehydroepiandrosterone (DHEA), androstenedione, testosterone and small 
amounts of DHT [116]. Depending on availability of steroidogenic enzymes, 
DHEA and DHEAS can be peripherally converted to estradiol, testosterone 
and DHT [117]. In premenopausal women about half of circulating 
testosterone arises from direct secretion from the ovary and the adrenal gland 
of equal amount. The remaining half is produced from peripheral conversion of 
adrenal and ovarian androgens [118]. Serum testosterone levels decline 
steeply in the early reproductive years, but do not change drastically at 
menopause [119]. Ovarian testosterone production is considered to continue 
after menopause [79, 120]. The postmenopausal ovary produces less 
testosterone in absolute quantities compared to the premenopausal ovary, but 
proportionally more (about half) of the circulating testosterone [118, 121] 
(Figure 5).  
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                          Premenopausal women                          
   
In premenopausal women, androstenedione is secreted by the adrenal cortex (50%), the 
ovary (40%), and converted from DHEAS (10%). Testosterone is secreted by the adrenal 
cortex (25%) and the ovary (25%) with the remaining 50% being produced from circulating 
androstenedione. 
                          Postmenopausal women 
 
In postmenopausal women, androstenedione is secreted to a greater extent by the adrenal 
cortex (70%) compared to premenopausal women and to a lesser extent from the ovary 
(10%). Testosterone originates mainly from the ovary (50%) and to a lesser extent from 
circulating androstenedione (40%) and the adrenal cortex (10%).  
Figure 5. Sources of androgens in premenopausal and postmenopausal women 
(percentages from Cameron et al. 2004 [116]). Dehydroepiandrosterone sulphate (DHEAS) is 
mainly a product of the adrenal cortex, and functions as a source of peripheral androgen 
production, for example in the ovary. Dehydroepiandrosterone (DHEA) is secreted by the 
adrenal cortex (50%) and the ovary (10%) and 40% is derived from circulating DHEAS. 
Dihydrotestosterone (DHT) is primarily a peripheral product of testosterone, but a small 
quantity is secreted directly by the adrenal gland. 
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Bioavailability and measurement of testosterone  
Sex hormone-binding globulin (SHBG), produced in the liver, is a major 
determinant of the bioavailability of sex steroids. SHBG has a high affinity to 
both estradiol and testosterone. Around 65–70% of circulating testosterone is 
bound and inactivated by SHBG, 30–35% is loosely bound by albumin and only 
0.5–3% represents freely circulating testosterone [122]. Since the binding of 
testosterone to albumin is rather weak, the free and albumin-bound fractions 
are defined as the bioavailable testosterone [123]. Oral estrogen is known to 
increase SHBG and thus lowering free testosterone, whereas androgens and 
progestin have the opposite effect [78]. 
 
The low concentration of free testosterone in female blood makes it difficult to 
obtain accurate measurements. Immunoassays are most commonly used in 
clinical practice, however, they are known for their inaccuracy due to cross-
reactivity with other steroids and sensitivity to high levels of SHBG [123]. The 
most accurate method to assess total testosterone is liquid chromatography-
tandem mass spectrometry (LC-MS/MS) [124]. Free testosterone can be 
calculated by equilibrium dialysis/ultrafiltration [123] or by the mass action 
equation based on total testosterone, SHBG and albumin concentrations 
[125]. The free androgen index (FAI) has been used as an approximation of 
free testosterone, and is calculated by dividing total testosterone 
concentration by SHBG concentration [126]. 
 
Free or bioavailable testosterone is traditionally considered the most reliable 
measure of tissue testosterone exposure [115] and the best determinant of 
overall clinical androgen status of women [127]. However, measurement of 
serum testosterone does not provide a specific measure of total tissue 
exposure or action [128]. In peripheral tissues, active steroids can be 
synthesized in the same cell as where their action is exerted, without release of 
the active steroids into the circulation [129]. The sensitivity of the androgen 
receptor differs between individuals, which may result in variability in end-organ 
response to circulating levels of androgens [115]. In summary, total androgenic 
action is determined by the level of androgens present in the circulation, the 
degree of binding to SHBG and albumin, the degree of inter-conversion to other 
androgens and estrogens, and the binding affinity of the androgen to the 
androgen receptor.  
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Biological effects of estrogens and androgens 
Estradiol is the most potent estrogen and the dominant sex hormone in 
women. Estradiol initiates and completes epiphyseal closure during puberty 
[130], thickens the vaginal mucosa, enlarges the uterus, and promotes growth 
of ductal system of the breast [131]. In the liver, estrogens increase 
lipoprotein receptors, resulting in a decrease in serum concentrations of low-
density lipoprotein cholesterol (LDL) [132]. Estrogens increase vasodilatation, 
promote angiogenic activity and inhibit apoptosis in endothelial cells [76]. 
Estrogens also cause increased coagulation activity [133].  
 
Androgens are precursor hormones to estrogens, but they also act directly 
through the androgen receptor in numerous tissues in the body, including the 
brain [134]. Androgens have anabolic properties on bone and muscle and 
increase erytropoesis [135]. Testosterone appears to affect mood, energy and 
sexuality in women, but the effects are less clear than in men [136]. 
Testosterone is thought to affect sexual arousal response in women [137]. 
Some studies have reported a correlation between higher endogenous 
androgen levels and better sexual function in women [138-153] whereas in 
other studies, no such correlation was found [128, 154-165] (Table 4).  
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SIDE-EFFECTS OF CERVICAL CANCER TREATMENT 
 
Since cervical cancer has high overall survival rates among women in young 
ages, treatment-related morbidity is an important aspect of cervical cancer 
survivorship. Issues of special concern to women with cervical cancer include 
threats to body image, sexuality and reproduction [169]. Surgical treatment can 
consist of removal of the uterus and ovaries, leading to permanent loss of 
fertility. Radiotherapy in premenopausal women is associated with onset of 
menopause. Chronic side effects can develop either directly from acute 
toxicities, or come years after completed cancer treatment. 
 
Side-effects of cancer treatment on ovarian function 
In toxicology, the median lethal dose (LD50) of a toxin or radiation is the dose 
required to kill half the members of a tested population. The LD50 for the human 
oocyte has been determined to be < 2 Gy [170]. When external beam 
radiotherapy is given, the total dose to the ovaries usually exceeds 45 Gy, thus 
resulting in destruction of the oocytes and complete cessation of estrogen 
production. In premenopausal women, this causes a sudden onset of 
menopause. Symptoms from iatrogenic menopause can include vasomotor 
symptoms, vaginal dryness, urinary incontinence and urinary tract infections, 
insomnia, mood changes, and loss of libido [171]. 
Iatrogenic menopause can also be caused by salpingo-oophorectomy (SOE), 
which is performed if there is a risk of tumor spread to the ovaries. However, 
there are also indications that hysterectomy alone can adversely affect 
ovarian function and shorten the time to menopause, even if the ovaries are 
not removed [172]. Reduction of the ovarian reserve after hysterectomy as 
measured by serum levels of FSH [173-178] and inhibin B [176] has been 
described. One study reported earlier ovarian failure in women having vaginal 
hysterectomy, but not following abdominal hysterectomy [179]. On the other 
hand, some investigators found no association between hysterectomy and 
age of menopause [180, 181], or levels of FSH [182].  
Circulating FSH rises in response to reduced inhibin and estrogen secretion 
from the ovarian follicles in the years before the menopause. However, single 
FSH measurements have limited ability to predict reproductive status, and no 
specific concentration of inhibin B has been shown to be diagnostically 
discriminatory [183]. Serum AMH has therefore gained increasing attention as 
a marker of reproductive ageing. 
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Reduction of ovarian reserve measured by AMH in cancer patients 
Serum AMH has been used as an assessment of damage to the ovarian 
follicle reserve due to various cancer treatments [184]. However, the effect of 
radiotherapy alone, or in combination with cisplatin, as treatment for cervical 
cancer has not been evaluated by AMH measurements. Among women 
treated with alkylating agents or pelvic or total body irradiation in childhood, 
serum levels of AMH are generally very low [185, 186]. Cisplatin is considered 
to have moderate gonadotoxic effects [187], and since the radiotherapy alone 
already has a detrimental effect on the ovarian follicles, it is unlikely the 
cisplatin has any additional effect. The effect of cisplatin alone, or in 
combination with topotekan or paclitaxel, has not been examined. 
 
The effect of radical hysterectomy on serum AMH-levels has not been 
investigated previously. Following simple hysterectomy (Table 5), a decline in 
AMH has been reported after 1 [188], 3 [189] and 4 [188, 190] months. Muraji 
et al. [191] compared AMH levels cross-sectionally and found lower values 
among previously hysterectomised women versus comparators. Other 
investigators did not find any decrease in serum AMH 3 months after 
laparoscopic [192-194] or abdominal [195] hysterectomy, or 2 years after any 
type of hysterectomy [196]. There is thus no consensus regarding effects of 
hysterectomy on serum AMH levels, and most studies have been small. In the 
largest study with 158 patients, no change in serum AMH was found [194]. 
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Treatment effects on serum androgens 
The effects of radiotherapy on ovarian androgen production are not well 
known. In a study from 1981, Janson et al. measured testosterone levels in 
serum among 14 premenopausal women undergoing radiotherapy (45 Gy) 
and found no reduction [197]. Inskip et al [198], 1994, measured serum 
testosterone and androstenedione in 9 pre- and postmenopausal women 
before and 4-12 months after radiotherapy (50 Gy) and found reduced levels 
only in the postmenopausal women (n=4).  
The ovarian stroma, where much testosterone synthesis takes place, seems 
to be more resistant to radiotherapy than the follicular tissue [198]. It is not 
known at which critical dose level androgen production from the ovaries is 
suppressed, but based on animal and human in vitro experiments it has been 
hypothesized to be at approximately 5-6 Gy [199]. A radiation effect on 
adrenal hormone production has been suggested [200], but has not been 
confirmed [198].  
The effect of chemotherapy treatment for cervical cancer (alone or in 
combination with radiotherapy) on androgen levels has not been examined. 
Bilateral SOE eliminates all ovarian sources of androgens, and SOE has been 
associated with a 15-50% decline in serum testosterone [120, 162, 201-203]. 
Cross-sectional studies among postmenopausal women showed that women 
with previous SOE had lower testosterone than non-oophorectomised women 
[119, 204-208].  
Aziz et al. [162], examined perimenopausal women before and one year after 
hysterectomy with ovarian conservation, and found a 15% reduction of FAI, 
but no change in total testosterone. Cross-sectional studies have found lower 
levels of total [204, 207, 208] and free [204, 207] testosterone among 
hysterectomised women compared to women after natural menopause.  
Table 6 summarizes measurements of serum androgens following 
radiotherapy and hysterectomy with or without SOE. The effects of 
radiotherapy on androgen levels are practically unknown [198]. Bilateral SOE 
seems to reduce testosterone up to 50% [120, 162, 201-203, 209], but 
smaller studies (n≤15) [120, 201, 203] and imprecise measurement methods 
[120, 162, 201, 202, 209] are limitations, and the use of hormone therapy 
(HT) [162] may have biased the results. Cross-sectional studies indicate that 
hysterectomised women have slightly lower testosterone levels than women 
after natural menopause [204, 207, 208], but prospective studies are mostly 
missing [162].
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Sexual dysfunction after cervical cancer treatment 
Sexual dysfunction is one of the most disturbing sequelae after treatment of 
cervical cancer [211, 212]. Several researchers [213-216] have tried to 
compile results from previous studies, which is difficult due to the use of 
different study designs and methods of evaluating sexual function. In 
questionnaire-based assessments, women have reported varying degrees of 
vaginal dryness [211, 217-223], dyspareunia [219, 220, 222, 224, 225], short 
vagina [211, 220, 222] and sexual dissatisfaction [218, 222].  
 
The pathophysiology of sexual dysfunction after cervical cancer treatment has 
several possible explanations, including both physical and psychological 
factors. Radical hysterectomy can result in vaginal fibrosis [215], and damage 
to the autonomic nerves [226], causing a reduction in vaginal blood flow and 
reduced lubrication [227]. Decreased blood flow and fibrosis can also occur as 
a consequence of radiotherapy [228]. Estrogen deprivation following 
radiotherapy or SOE leads to atrophy of the genital organs and diminished 
vaginal lubrication [229]. 
 
Androgen deficiency as a cause for sexual dysfunction 
Testosterone is important for the maintenance of musculoskeletal health and 
brain function in women [230], but it is in the treatment of hypoactive sexual 
desire disorder (HSDD) that testosterone has attracted the most attention 
[231]. HSDD is defined as deficiency of sexual desire causing personal 
distress [232]. In 2002, the term female androgen insufficiency syndrome 
(FAIS) was used as a definition for decreased libido and wellbeing, persistent 
fatigue, bone loss and decreased muscle mass in the presence of low levels 
of bioavailable testosterone and normal estrogen status [127]. The term FAIS 
is, however, not used today due to the lack of correlations between specific 
androgen levels and symptoms [233, 234]. The prevalence of low sexual 
desire has been reported high – 33% – among Swedish women, but the 
prevalence of sexual problems associated with personal distress was 14% 
[235] (12% in the US [236]).  
 
It is difficult to correlate endogenous androgen levels to sexual function (Table 
4), and considering publication bias and lack of consistency in the findings, 
probably no such simple association exists in healthy women. However, 
randomized studies with testosterone therapy have shown improvements in 
outcome measures such as sexual activity, desire, wellbeing, and reduced 
distress [237-242]. A Cochrane analysis concluded that testosterone treatment 
in addition to standard HT can improve sexual function in postmenopausal 
women with self-reported low libido [243]. Testosterone therapy in women has 
not been found to have adverse effects on cardiovascular disease, 
endometrium [244] or breast [245]. Therefore testosterone can be used to 
treat HSDD [246].  
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Associations between androgen levels and sexual dysfunction among cervical 
cancer survivors have not been examined. Among breast cancer survivors, 
Alder et al [164] examined 29 premenopausal women. The only two factors that 
were associated with sexual function were relationship quality and the use of 
chemotherapy, not androgens or their metabolites. Speer et al. [163] 
investigated sexual function in 55 breast cancer survivors. No correlation was 
found between hormonal levels and sexual functioning. In that study, 
depression and having traditional role preferences were the most important 
determinants of low sexual desire. Greendale et al. [158] investigated 61 
postmenopausal breast cancer survivors and found that higher levels of 
bioavailable testosterone were associated with less sexual interest.  
 
The use of testosterone therapy among female cancer survivors has only 
been examined in one randomized controlled trial [247] comparing transdermal 
testosterone and placebo for the improvement of sexual desire in 150 female 
survivors of mixed cancers who were not using estrogen supplements. Serum 
levels of bioavailable testosterone increased in the intervention group, but there 
were no group differences in sexuality scores from before to after treatment, 
perhaps because the women were also estrogen deprived. 
 
Morbidity associated with early menopause 
The term premature ovarian failure, or premature ovarian insufficiency (POI), 
refers to menopause before 40 years [248]. Early menopause refers to 
menopause at 45 years or younger [249]. Spontaneous premature ovarian 
insufficiency affects approximately 1% of all women [248] and is usually 
idiopathic, but can also be caused by autoimmune disorders, genetic causes, 
infections or inflammatory conditions, enzyme deficiencies, or metabolic 
syndromes [250]. Iatrogenic early or premature menopause can be induced by 
radiotherapy or chemotherapy as cancer treatment, or by surgical treatment 
(bilateral SOE) [81]. 
 
Early menopause is associated with osteoporosis and increased fracture risk 
[251, 252], coronary heart disease [253-256], stroke [255-257], cognitive 
impairment [258], cardiovascular mortality [254, 259-263], and total mortality 
[254, 261, 264-266]. Among women undergoing bilateral SOE, cardiovascular 
mortality [262, 263] and all-cause mortality [266] have been reported to be 
higher among women not taking estrogen after surgery. Endothelial dysfunction 
has been suggested to contribute to the increased risk of cardiovascular 
disease and mortality in women with POI. In one study, HT restored endothelial 
function within 6 months of treatment [267]. 
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Hormone therapy (HT) for women with natural and early menopause 
Exogenous estrogens are used as HT among healthy women for menopausal 
symptoms, such as hot flashes. HT also reduces postmenopausal vaginal 
dryness, improves sexual function [268] and reduces the risk of osteoporotic 
fractures [269]. However, long-term use of combined continuous HT (estrogen 
plus progestin) in older postmenopausal women increases the risk of 
coronary heart disease, venous thromboembolism, stroke, breast cancer, 
gallbladder disease, dementia, and death from lung cancer [269]. Following 
reports of negative effects of HT, for instance from the famous Women’s 
Health Initiative trial [270], HT use has decreased among women 50-59 years 
of age [271]. Importantly, age and time since menopause seems to influence 
the risk/benefit associated with HT. This concept is called the timing or window 
of opportunity hypothesis [272, 273]. Thus, in women starting the treatment 
less than 10 years since menopause, HT use is associated with decreased 
risk of coronary heart disease and reduced overall mortality rate despite a 
small increased risk of breast cancer after longer use [274]. 
  
The potential risks associated with postmenopausal HT do not at all apply to 
women with early or premature menopause [275]. HT in these women has 
been shown to counteract loss of bone mass [276] and decrease the risk of 
cardiovascular death [262]. Furthermore, women with early menopause 
already have a decreased risk of breast cancer [277], which dose not 
increase with HT [278].  
 
In light of the above, HT is recommended for women with premature or early 
ovarian insufficiency to reduce morbidity and mortality, and should be used at 
least until the average age of natural menopause. Contraindications to HT 
among women in early menopause are the same as for perimenopausal 
women [279], i.e. hormone-dependent tumor, undiagnosed genital bleeding or 
endometrial hyperplasia, untreated hypertension, arterial or venous 
thromboembolic disease, porphyria cutanea tarda, and active liver disease 
[280]. Estrogen doses should be high enough to achieve serum levels within 
physiological levels of fertile-aged women [281]. Therefore, women with early 
menopause may need higher estrogen doses than women who use HT to 
relieve symptoms after natural menopause [82].  
 
Hormone therapy in cervical cancer survivors 
Squamous cell cancer, which is the most common histopathological type of 
cervical cancer, is not considered to be an estrogen-responsive disease [29], 
and HT after treatment of squamous cell cancer is uncontroversial [282-286]. 
On the contrary, for adenocarcinoma, the safety of HT use among survivors 
has been questioned, based on reports of an association between HT use 
and cervical adenocarcinoma [28, 29].  
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In a population-based study by Jaakkola et al. [29], a decreased risk of 
squamous cell cancer (standardized incidence ratio (SIR) 0.34, 95% 
confidence interval (CI) 0.16-0.65), but an increased risk of adenocarcinoma 
(SIR 1.83, 95% CI 1.24-2.59), was found in association with 5 years of HT-
use. In absolute numbers, among 10,000 women followed for 10 years who 
used HT > 5 years, these association translated to 2-3 fewer cases of cervical 
squamous cell carcinoma, but 2 more cases of adenocarcinoma than among 
average Finnish women. Lacey et al. [28] conducted a case– control study of 
124 women with adenocarcinomas, 139 women with squamous cell 
carcinomas, and 307 matched controls. No significant associations were 
found for ever-use of HT, but unopposed estrogens were positively 
associated with adenocarcinomas (odds ratio (OR) 2.7, 95% CI 1.1-6.8).  
Several other studies have not shown increased risk of cervical cancer in 
general in association with HT use [287-290], however in these studies no 
distinctions were made between adenocarcinoma and squamous cell cancer. 
Only one study has investigated the safety of HT after cervical cancer 
treatment. Ploch et al. prospectively compared 80 women with HT and 40 
comparators following surgery or radiotherapy for stage I or II cervical cancer 
over a period of 5 years [291]. They found no difference in disease recurrence 
or overall survival between the two groups. According to present knowledge, 
there is no evidence to suggest that HT cannot be safely administered to 
cervical cancer survivors up to age of natural menopause [171, 291, 292].  
Cardiovascular disease  
Due to the associations between early menopause and cardiovascular 
disease [253-257, 259-263], in addition to the well-established associations 
between smoking and cervical cancer [32], and smoking and cardiovascular 
disease [293], cervical cancer patients would be expected to be at increased 
risk of cardiovascular disease. However, the few studies on this topic have 
shown diverging results. The risk of stroke was found increased (5-year 
cumulative risk: 8% vs 5%) [294], decreased (adjusted hazard ratio (HR) 0.58, 
95% CI 0.54-0.61) [295] or with no difference versus the general population 
[296]. For ischemic heart disease, previous results are also contradictory. The 
risk of myocardial infarction was found doubled after SOE, but not significantly 
increased after radiotherapy in a study by Hsieh et al. [297]. Maduro et al. [296] 
and Tsai et al. [294] both found increased risks of myocardial infarction among 
cervical cancer patients (doubled versus the general population and 60% 
higher risk versus comparators). In Sun et al. [298], cervical cancer patients 
were found to have a 43% lower risk of ischemic heart disease (defined as 3 
diagnoses of ICD9 410 to 414). However, the decreased risk was mainly found 
in patients above 50 years of age, and in those with a follow-up of 3 years or 
less. The use of HT was also investigated in that study [298], and HT use was 
associated with a lower risk of ischemic heart disease among cervical cancer 
patients using HT versus cancer-free comparators not on HT.  
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Fragility fractures 
Menopause increases the risk of osteoporosis and fracture due to a decrease 
in serum estradiol, but can also be mediated by decreased levels of 
androgens [299]. Estradiol inhibits bone turnover by binding to estrogen 
receptors on osteoblasts and osteoclasts [300]. Androgen action on bone 
depends on aromatization of androgens into estrogens, but can also be 
directly mediated [301]. The mechanisms by which radiotherapy affects bone 
are likely a combination of direct cellular effects and vascular ischemia [302]. 
The 2 to 5-year cumulative incidences of pelvic insufficiency fractures among 
women treated with external beam radiotherapy have been reported to be 5-
45% [302-307] (but with no comparison group). In most studies, high age 
[302-304, 306] and low body weight [303-306] have been reported as 
additional risk factors. 
 
Secondary cancers 
Several large studies have reported cervical cancer survivors to be at 
increased risk of developing secondary cancers [308-311], with around 30% 
more cancer cases overall than in the population. Patients treated with 
radiotherapy developed cancers at heavily irradiated sites (colon, 
rectum/anus, urinary bladder, genitals) [308, 311] consistent with a radiation 
etiology, but patients who did not receive radiotherapy also had an increased 
risk of cancer of pharynx, genitals, and rectum/anus, suggesting a HPV 
etiology [308, 310]. The incidences of cancers related to smoking, including 
cancers of the urinary bladder, lung and bronchus were also increased [308, 
310, 311].  
 
Quality of life in cervical cancer survivors 
Health-related quality of life (QoL) is usually assessed by patient 
questionnaires, which can be generic (i.e. could be used in any population) or 
disease-specific. Four questionnaires have been validated among cervical 
cancer survivors: The European Organization for Research and Treatment of 
Cancer Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-
CX24 [312, 313], the Female Sexual Function Index (FSFI)[314], the Leiden 
Questionnaire [315], and the Sexual Function-Vaginal Changes Questionnaire 
[316]. The FSFI [317] and EORTC QLQ-CX24 [312] have validated Swedish 
versions.  
 
Two systematic reviews have evaluated studies on different dimensions of QoL 
among cervical cancer survivors [214, 216]. Both indicate difficulties in 
comparing results from different studies and drawing general conclusions, due 
to the variety of questionnaires used and heterogeneity of participants. Findings 
regarding physical and psychosocial wellbeing vary considerably, while findings 
concerning sexuality are more consistent [214].  
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Most studies have shown that QoL in cervical cancer survivors is reduced 
compared with the general population. Apart from sexual dysfunction 
(described earlier), impaired anorectal and gastrointestinal function, urinary 
symptoms, and lymphedema are the most commonly reported distressful 
symptoms [214, 216]. 
 
Gastrointestinal morbidity 
 
Bowel dysfunction stems from surgical damage to the lumbosacral nerve 
plexus [318, 319], postoperative adhesions [320] or as a consequence of 
radiotherapy. Radiotherapy causes gastrointestinal mucosal inflammation and 
can lead to ischemia and fibrosis [321], chronic proctitis or enteritis, bile acid 
malabsorption and bacterial overgrowth [322]. Constipation [323], tenesmus 
[217], diarrhea [222, 323-326], and fecal incontinence [318] are patient-
reported symptoms, associated with much distress [212].  
 
Urologic morbidity 
Lower urinary tract dysfunction after radical hysterectomy can occur as a 
consequence of surgical damage to the pelvic nerve plexa when resecting the 
cardinal ligaments and sacrouterine ligaments. Damage to the 
parasympathetic nerves results in a hypocontractile bladder with decreased 
sensation, whereas damage to the sympathetic system leads to reduced 
bladder compliance, increased storage pressure and bladder neck 
incompetence, resulting in urinary incontinence [327]. Radiotherapy can 
cause microvascular damage, inflammation and fibrosis. Late urological 
complications to radiotherapy are cystitis, ureteric stenosis, fibrotic shrunken 
low-compliance bladder, and fistula formation [328]. Urinary symptoms are 
frequent following both surgery and radiotherapy and include incontinence 
(33-53%) [216, 217] as well as voiding dysfunction (53-81%) [216, 217, 329]. 
Among long-term survivors (5 to 15 years), women treated with radiotherapy 
were more affected by voiding problems [330].  
Lymphedema 
 
Radical hysterectomy includes removal of the external iliac, internal iliac and 
obturator lymph nodes, thus disrupting the lymph drainage routes. Secondary 
lymphedema of the legs and genital area is a common side effect due to the 
accumulation of lymph in the subcutaneous fat, leading to edema, chronic 
inflammation and fibrosis. Patients may present with varying degrees of 
severity, from mild swelling to large edematous enlargement. Lymphedema is 
one of the most disabling symptoms [211, 331] and unlike other symptoms, 
may worsen over time [325, 330, 332]. The prevalence of lymphedema has 
been reported 2-26% [329, 333-338] with a higher prevalence after radical 
hysterectomy in combination with radiotherapy [212, 330, 334, 337, 338]. 
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Psychological wellbeing 
 
Compared to the general population, long-term cervical cancer survivors had 
more mental fatigue and anxiety in a study by Le Borgne et al. [330]. 
Mantegna et al. [331], found an improvement over time regarding emotional 
distress, but elevated anxiety levels were still present 2 years after treatments 
in approximately 12% of early-stage and in 16% of locally advanced relapse-
free cervical cancer patients (no comparison group). Conflicting results were 
reported by Kim et al. [339], who investigated 828 cervical cancer survivors 
(mean time since diagnosis 7 years) and who found that anxiety scores did not 
differ from those of healthy comparators and that depression scores were 
lower. Among young (21-49 years old) survivors of mixed gynecological 
cancers, 63/88 women reported distress in relation to loss of, or impaired 
fertility, and their levels of distress and depression were associated with the 
severity and number of menopausal symptoms [340]. 
 
Work loss and cancer 
A challenge of treating cancer is not only to find efficient therapies for the 
disease, but also to minimize medical and social hazards [341]. The ability to 
work following cancer treatment is important for maintaining self-esteem, 
identity, and living conditions. It is also important for society to keep people 
employed for economic reasons and to prevent social inequity [342]. 
Investigations on work loss among cancer patients therefore involve aspects 
of cancer care and rehabilitation.  
Studies on cancer patients in general have reported return-to-work rates of 
24-94% [343, 344] increasing with time from cancer diagnosis. Nevertheless, 
some patients suffer from health problems, which lead to partial or total work 
disability [345]. A meta-analysis showed that cancer survivors overall were 
more likely to be unemployed than healthy comparators: 34% versus 15% 
[346]. Cancer patients do not differ from the population in that higher 
education and better social climate at work is associated with better work 
ability and that old age and co-morbidity reduce work ability [347]. However, 
other individual and treatment-related factors also influence work disability in 
cancer survivors [343, 344, 348-351], and therefore results for other cancer 
patients may not be readily generalizable to cervical cancer survivors. 
Three questionnaire-based studies investigated return to work in relation to 
cancer treatment [352-354]. In the study by de Boer et al. [352], return to work 
was measured at 2, 12 and 18 months after treatment of different cancers with 
curative intent. In the whole cohort, patients treated with additional 
chemotherapy and radiotherapy had a 2.4 times higher risk of staying off work 
compared to patients treated with surgery alone. Also in the study by Amir et al. 
[353], treatment modality was a significant factor that predicted return to work 
within 18 months. The highest proportion of returnees was found among those 
who received surgery alone (93%) and the lowest (71%) in those treated with 
radiotherapy, chemotherapy or hormone therapy. In the study by Molina et al. 
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[354], 59% of the cancer patients returned to work within 6 months after 
diagnosis. The strongest predictors for remaining in employment were young 
age, complete response and lack of sequelae of the disease and its treatment.  
 
Spelten et al. [355] examined the impact of fatigue in return to work among 235 
cancer patients, of which 56 were diagnosed with female genital cancer. 
Fatigue levels six months after the start of sick leave predicted return to work at 
18 months, independent of diagnosis and treatment. 
 
Sick leave and return to work among gynecological cancer survivors 
Evaluations of work loss specifically among cervical cancer patients are rare. 
Two register-based studies have presented results for cervical or gynecological 
cancer patients [342, 356]. Roelen et al. [356], investigated return to work in 
5074 employees, of which 855 were diagnosed with gynecological cancer. 
Median duration of sickness absence in this subgroup was 105 days during the 
first 2 years following diagnosis, and 88% had full return to work within 2 years. 
In the study by Torp et al. [342], 96 (8%) of the 2008 individuals included in 
1999 and alive in 2004, at end of follow-up, were cervical cancer patients. Odds 
ratio for sick leave 5 years after diagnosis, adjusted for socio-demographic 
factors and sick leave before diagnosis was non-significantly increased for the 
subgroup of cervical cancer patients (1.34, 95% CI 0.85-2.12) compared to a 
cancer free comparison group.  
 
A variety of factors influence the decision whether or not to return to work. In a 
study by Nachreiner et al. [357], gynecological cancer survivors reported 
challenges in work performance including physical tasks such as lifting, 
stooping, crouching or kneeling, but also concerns about the effect on 
concentration, analyzing data and learning new things. 
 
Several studies [358-360], including a meta-analysis [346], have reported 
higher unemployment rates among gynecological cancer survivors compared 
to the general population (49% vs 38%; pooled relative risk (RR), 1.3, 95% CI 
1.2-1.4). The effect of co-morbidity on unemployment was examined by Yoo et 
al. [360] in a study including 858 cervical cancer survivors in Korea. The 
percentage of unemployed survivors increased from 51% to 73% after 
treatment, and two or more co-morbidities (adjusted OR 1.8, 95% CI 1.1-2.9) 
were associated with unemployment.  
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Table 7 presents a summary of studies with data on work loss in cervical or 
gynecological cancer patients. Most patients returned to work after completed 
treatment [356, 361]. The rate of return to work, and work ability, increased with 
time from diagnosis [352, 362] and 5 years from diagnosis, sick leave rates 
were not significantly increased [342]. Compared to the general population, 
women with a history of gynecological cancer had an increased risk of 
unemployment [358, 359], especially when other morbidity was present [360], 
however there was no excess unemployment when adjustment was made for 
socio-demographic and work-related variables [363]. Women treated with 
radiotherapy took longer time to return to work [364]. No study assessed the 
impact of cancer recurrence on sick leave or unemployment. 
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SUMMARY OF AIMS AND RATIONALE   
The overall aim of the thesis is to generate knowledge of short- and long term 
consequences of cervical cancer treatment, to provide a basis for improvement 
of the quality of life of cervical cancer survivors. Knowledge of factors 
associated with post treatment morbidity may also benefit patients with other 
cancers treated similarly, such as the endometrial, ovarian, vulvar, vaginal, 
bladder, anal and rectal cancer. 
 
The specific research questions were:  
 
I: How are serum levels of AMH affected by cervical cancer treatments?  
 
Rationale: Previous studies have indicated an increased risk of early 
menopause after hysterectomy [172-177]. Because early menopause is 
associated with increased morbidity and mortality [251-266] and HT reduces 
these risks [262, 263, 266], it is important to ensure adequate hormone 
substitution in such cases [82]. Hysterectomised women have no menses, and 
therefore the onset of menopause may go unnoticed. AMH is already being 
used as a marker of iatrogenic damage to the ovarian follicle reserve, due to 
radiotherapy [185, 186], chemotherapy [185, 367], uterine artery embolization 
[196], simple hysterectomy [189-195], or ovarian surgery [368, 369]. However, 
measurements of AMH before and after radical hysterectomy have not been 
performed previously. A decline in AMH that is larger than the expected 
decline due to normal ageing could indicate a risk early ovarian failure.  
 
II: How are serum levels of androgens affected by cervical cancer treatments 
and is there an association between low testosterone levels and low sexual 
function in this patient group?  
 
Rationale: Sexual dysfunction is common among cervical cancer survivors 
[216], and the causes are likely multifactorial. It is not known if androgen 
deficiency contributes to sexual dysfunction among cancer survivors, since 
the impact of radiotherapy on ovarian androgen production is largely unknown 
[197-199]. If low androgen levels could be demonstrated among women 
treated for cervical cancer and if low levels would be associated with sexual 
dysfunction, the logical consequence would be to offer these women the 
possibility of testosterone treatment, which has proven effective in the 
treatment of hypoactive sexual desire and arousal disorders among naturally 
postmenopausal women [243, 246].  
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III: To what extent do women in early menopause due to cervical cancer 
treatment use HT?  
 
Rationale: HT is recommended to women in early menopause up to the age of 
natural menopause [80-82] for menopausal symptoms and to reduce risks of 
cardiovascular disease and osteoporosis [279]. HT use has diminished after 
reports of risks associated with long-term use [271]. The general fear of HT 
could have led to an underuse also among women in early menopause, 
however, no study on patient and doctor adherence to the recommendations 
on HT use among cervical cancer survivors has been performed previously. 
 
IV: Do cervical cancer survivors have an increased risk of work loss? 
 
Rationale: The extent of sick leave and disability pension after a cancer 
diagnosis can be expected to vary greatly between cancer forms, due to the 
variations in age at diagnosis, prognosis and treatment [370]. Previous studies 
in this area including cervical or gynecological cancer patients had limited 
clinical data and could therefore not distinguish between sick leave due to 
cancer relapse and sick leave among cured patients [342, 352, 353, 356, 371]. 
In the absence of relapse, an increased risk of sick leave and disability pension 
may be viewed as a proxy for severe side effects of treatment, which potentially 
could be prevented or treated.
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STUDY I-II: CLINICAL STUDIES 
Investigations I and II are based on a pilot study, including data collected from 
a one-year cohort of cervical cancer patients at Radiumhemmet, Karolinska 
University Hospital from September 1st 2008 to August 31st 2009.  
 
Population 
The aim was to include all women eligible for cervical cancer treatment. 
Exclusion criteria were: 
 
1. Inability to communicate in Swedish (because we used questionnaires in 
Swedish). 
2. WHO performance status [372] two or higher (no curative treatment 
possible). 
 
At their first visit, before clinical staging and treatment, the women were asked 
to participate in the study. A total of 92 patients were asked to participate, of 
whom 71 consented (77%). From these women, a subgroup was chosen for 
analysis of AMH levels (Figure 6), consisting of women < 45 years of age, 
treated with chemoradiotherapy or radical hysterectomy. The women treated 
with trachelectomy (n = 3) were not analyzed further due to the small number. 
The study population in study I thus consisted of 32 women.  
 
 
 
  
 
Figure 6. Flow-chart of the participants in Study I. 
 
  
Eligible for inclusion
N=92
Included in study
N=71
Declined 
n=21
Lost to follow-up
n=3
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From the 71 women originally included in the study, 11 were lost to follow-up, 
mainly due to cancer progression. In study II, we selected all women with 
complete before and after treatment blood sampling (n = 60). 
 
Exposure 
Data on tumor stage (according to FIGO) and treatment(s) were obtained from 
the women’s medical charts. The participants were then divided into groups 
according to how their individual treatment(s) affected ovarian sex hormone 
production. The groups in study I were defined as: 
 
Treatment group 1: Chemoradiotherapy only, no surgery (n = 17). 
Treatment group 2: Hysterectomy, pelvic lymphadenectomy and SOE with or 
without preoperative brachytherapy with or without postoperative 
chemoradiotherapy (n = 6).  
Treatment group 3: Radical hysterectomy and pelvic lymphadenectomy with 
ovarian preservation (n = 9). 
 
The treatment groups in study II were defined as: 
 
Irradiated ovaries: Radiotherapy (with or without chemotherapy) without 
surgery or ovarian-sparing surgery and postoperative radiotherapy (with or 
without chemotherapy) (n = 38)  
Removed ovaries: Radical hysterectomy, pelvic lymphadenectomy and SOE 
with or without radiotherapy or chemotherapy (n = 10) 
Preserved ovaries: Ovarian-sparing radical hysterectomy or trachelectomy and 
pelvic lymphadenectomy (n = 12).  
 
Outcome 
Blood-sampling and measurement 
 
Blood samples were taken at baseline, 1-2 weeks after brachytherapy or 
radiotherapy, and one year after the last treatment (but results will only be 
presented for the baseline and 1-year blood samples). For practical reasons, 
the blood sampling had to be performed opportunistically regarding time of day 
and menstrual cycle day. Blood samples were allowed to clot for 30-60 
minutes, and after centrifugation for 10 minutes in 3000g, the serum was 
placed in a freezer at -20°. The analyses were performed in batch.  
 
Details of the different hormone assays are described in Table 9. Serum AMH 
was determined by enzyme linked immunoabsorbent assay AMH Gen II ELISA 
by Beckman Coulter. Detection limit reported by the manufacturer was 0.08 
µg/L, within and between assay coefficient of variation 5.4% and 5.6%, 
respectively. The normal reference range of serum AMH by this method at the 
Department of Clinical Chemistry, Karolinska University Hospital is 0.7-6 µg/L.  
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Serum levels of FSH, LH, SHBG, androstenedione and DHEAS were 
determined by direct chemiluminescent immunometric assay (Immulite, 
Siemens) and levels of estradiol were determined by radioimmunoassay 
(Spectria, Orion Diagnostica).  
 
Total testosterone was determined by liquid chromatography-tandem mass 
spectrometry (MS Quattro Premier, Xevo TQ MS). Detection limit was 0.1 
nmol/L and within and between assay coefficient of variation 2.7 (7%) and 13 
(6%), respectively. Concentrations of free testosterone were determined by 
calculations including testosterone, SHBG and a fixed concentration of albumin 
(40 g/L)[373] using the Södergård equation [374].
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Quality of life assessment 
 
Aspects of quality of life were assessed at baseline and at one-year follow-up. 
At baseline (date of inclusion, before start of treatment), the women were asked 
to assess their scores before the start of cancer symptoms. At one-year follow-
up, (i.e. one year after end of treatment) they were asked to answer the 
questionnaires concerning mood and symptoms during the past four weeks. 
The women completed three questionnaires, but here, results will only be 
presented from the FSFI questionnaire. The questionnaires were completed in 
conjunction with a hospital visit.  
 
The female sexual function index (FSFI) is an assessment tool for female 
sexual dysfunction [375]. The 19-item survey assesses 6 domains of sexual 
function: desire (2 items), arousal (4 items), lubrication (4 items), orgasm (3 
items), satisfaction (3 items) and discomfort/pain (3 items). The responses are 
graded on a scale from 0 or 1 to 5. A scoring algorithm is generated to assess 
each domain. Domain scores are obtained by summing the scores of the 
questions in each domain, and then multiplying the sum by the domain factor. 
The total score, which ranges from 2 to 36, is obtained by summing the six 
domain scores. A higher score means better sexual function. The clinical cut-off 
indicating sexual dysfunction is 26.5 [376], but for a diagnosis of female sexual 
dysfunction it needs to be combined with a measurement of distress [377]. 
The Swedish version of the FSFI was examined in a population of women 
with and without a diagnosis of HSDD and showed good reliability 
(Cronbach's alpha: 0.90-0.96, test-retest r=0.86-0.93), and correlation 
between the FSFI and the sexual function questionnaire (SFQ) (r=0.74-0.87) 
[317]. The FSFI is recommended as a measure of symptom severity for 
heterosexual women, who have been sexually active in the past 4 weeks 
[377].  
 
Follow-up 
The women were followed from date of inclusion up to one year after treatment, 
at the latest August 31st 2010. 
 
Ethical permission 
The study was approved by the Regional Research Ethics Committee in 
Stockholm (Dnr 03-645). Written informed consent was obtained from all 
women. 
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Statistical analyses  
To compare differences between groups, parametric tests can be used if the 
data is normally distributed. However, the Shapiro-Wilks test [378] showed 
that much of the data was not normally distributed. Therefore, the following 
non-parametric tests were used: 
The Wilcoxon signed-rank test [379] was used to compare hormone levels 
from before to after treatments in studies I and II and FSFI scores from before 
to after treatments in study II. 
The Mann–Whitney U test [380] (also called the Wilcoxon rank-sum test) was 
used to compare androgen levels between pre- and postmenopausal women, 
and to compare age and hormone levels between women with FSFI < 26.5 
and women with FSFI ≥ 26.5 at one-year follow-up.  
 
The Kruskal–Wallis test [381] was used to compare differences in hormone 
levels and FSFI scores between the three treatment groups.  
 
McNemar’s test [382] was used to compare the proportions of women with 
low sexual function (FSFI < 26.5) from before to after treatment. 
 
Fisher’s exact test [383] was used to compare the proportions of women with 
low sexual function before and after treatment in the three groups, and to 
compare factors that may affect sexual function among women with FSFI < 
26.5 and women with FSFI ≥ 26.5 at one-year follow-up. 
 
Spearman’s rank correlation coefficient [384] was used to investigate 
correlations between androgen levels and FSFI scores. 
 
All statistical tests were two-sided and p < 0.05 was considered significant. 
Statistical analyses were performed using IBM SPSS Statistics version 20 and 
22. 
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STUDY III-IV: REGISTER STUDIES 
Studies III and IV are register-based studies, where record linkage between the 
different registers was possible through the personal identification number 
assigned to all Swedish residents [385].  
 
Registers used 
 
The Swedish Cancer Register [386] was founded in 1958 and is maintained by 
the National Board of Health and Welfare (NBHW). It is estimated to cover 96% 
of all cancer cases in the population [387]. The register contains data on tumor 
site and histology according to the International Classification of Diseases 
(ICD) [388], date of diagnosis and reporting hospital. Tumor stage according to 
FIGO is also included from the year 2003 and onwards with gradually 
increasing coverage. 
 
The Swedish National Patient Register (NPR) [389] is maintained by the 
NBHW. The NPR was established in 1964-65 and has covered the entire 
Swedish population since 1987. It provides dates of hospital admissions in 
Sweden and discharge diagnoses coded according to ICD. Until 1996 up to 6 
discharge diagnoses and operation codes were permitted and a national 
classification of procedures was used based on an American classification of 
surgical procedures. After 1996 up to 8 discharge diagnoses were permitted 
and up to 12 operation codes from the Swedish Classification of Operations 
and Major Procedures. The ICD-9-classification was used 1987-1996 and the 
ICD-10 from 1997. From 1997, day-surgery was also included in the register 
and from 2001 specialized outpatient visits. The validity of the NPR is regarded 
as high [390]. 
 
The Prescribed Drug Register [391], maintained by the NBHW, was 
established on July 1st   2005 and holds data on dispensed prescriptions (not 
prescriptions actually issued by physicians) to the whole population of 
Sweden, including dispensed item (substance and formulation), amount, date 
of dispensing, and the prescriber’s profession and practice. All drugs are 
classified according to the Anatomical Therapeutic Chemical (ATC) 
Classification System [392]. The register does not include data on over the 
counter medications and drugs used in hospitals.  
 
The Total Population Register [393] started in 1968 and is maintained by 
Statistics Sweden (SCB). It records dates of emigration and death of all 
residents in Sweden, and is continuously updated. 
 
The Longitudinal integration database for health insurance and labour market 
studies (LISA) [394] is maintained by SCB since 1990 and includes all 
individuals from 16 years of age that were registered in Sweden as of 
December 31 each year. The database integrates data from the labor market, 
educational, and social sectors and is updated each year.  
 
  
	   Patients	  and	  methods	   	  	   	  
59 
The MikroData för Analys av Socialförsäkringen (MIDAS) [395] is maintained 
by the Swedish Social Insurance Agency (Försäkringskassan). It holds 
information on compensation for sickness, rehabilitation, work injury, and 
permanent disability. Only sick leave episodes >14 days are recorded, since 
the first two weeks of sick leave are paid by the employer. Disability pension 
is recorded from the first day. 
 
Populations 
Women with first incident cervical cancer were identified through the Swedish 
Cancer Register.  
 
In study III (Figure 7), we selected women 45 years or younger at diagnosis. To 
ensure a minimum follow-up time of 1.5 years after diagnosis, women who died 
or emigrated within this time period were excluded. Also, women with previous 
breast cancer were excluded, since it is usually a contraindication for HT. The 
prescribed drug register has information on dispensing from July 1st   2005 and 
therefore the time period January 1st 2005 to Sep 30th 2009 was chosen, to 
ensure that information on dispensing from 0.5 to 1.5 years after diagnosis was 
available for all patients at the time of our investigation in 2011.  
 
 
 
 
 
Figure 7. Flow-chart of participants and registers used in Study III. 
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In Study IV (Figure 8), we selected women aged 18-60 years at cervical cancer 
diagnosis during the period January 1st 2003 to December 31st 2009. Randomly 
selected general population comparators were individually matched to the 
cervical cancer patients by age, calendar year, region of residence and highest 
attained education level before diagnosis/match date. The comparators were 
not allowed to have a history of cervical cancer at the time of diagnosis of the 
matched case, and were censored in case of cervical cancer during follow-up. 
1718 patients (87%) were matched to five comparators each, 78 patients (4%) 
were matched to four, 52 patients (3%) were matched to three, 73 patients 
(4%) were matched to two, and 50 patients (3%) were matched to one 
comparator each.  
 
 
 
 
 
Figure 8. Flow-chart of participants and registers used in study IV. 
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Exposure 
The exposure was cancer treatment. Codes for surgical and oncological 
procedures from 6 months before, up to one year after the cervical cancer 
diagnosis, were taken from the NPR and defined the cancer treatment of each 
individual (Appendix).  
 
In study III, the women were divided into 3 groups based on cervical cancer 
treatment regimen: 
 
• Those expected to have estrogen deprivation due to bilateral SOE or 
radiotherapy were categorized as “in need of HT”.   
• Women treated surgically without SOE or radiotherapy (ovarian-sparing 
surgery) were categorized as “not in need of HT”.  
• Women who had unilateral SOE or received chemotherapy without 
radiotherapy were categorized as “in potential need of HT”, since 
unilateral SOE may be associated with early menopause [396] and 
some chemotherapeutic agents affect ovarian function [397].  
 
Women with a previous history of uni- or bilateral SOE (at any time point 
between 1987 and the uterine cervical cancer diagnosis) were classified 
according to their final treatment status (hysterectomy and unilateral SOE or 
hysterectomy and bilateral SOE).  
 
In Study IV the women were divided into 4 major treatment groups, and these 
treatment groups may be seen as proxy variables for cancer stage: 
 
• Fertility-sparing treatment (conization or trachelectomy) (very early 
stages) 
• Hysterectomy alone, no radiotherapy or chemotherapy (early stages) 
• Hysterectomy plus chemo- and/or radiotherapy (early stages with 
adverse prognostic factors) 
• Chemo- and/or radiotherapy, no surgery (advanced stages) 
 
In study IV cancer relapse was defined at the first registration in the NPR of an 
ICD-code for a secondary malignant tumor (Appendix), i.e. metastasis, at the 
earliest 6 months before cervical cancer diagnosis. If a woman received 
radiotherapy or chemotherapy in combination with a diagnosis of cervical 
cancer more than one year after primary cervical cancer diagnosis she was 
also classified as having a relapse. 
 
  
  
	   Patients	  and	  methods	   	  	   	  
62 
Outcome 
In study III, information on dispensing of contraceptives (G03A), estrogens 
(G03C), progestogens (G03D) and progestogens and estrogens in combination 
(G03F) were obtained from the Prescribed Drug Register. The drugs were 
further classified in subgroups of HT according to type of hormone and 
formulation as follows: patch/gel/oral estrogens with or without progestogens, 
contraceptives, or vaginal estrogen.  
 
HT dispensing was summarized in half-year intervals starting from the date of 
diagnosis to end of follow-up. Women were defined as prevalent users of HT in 
a specific interval if they had at least one dispensing during that time, among all 
women who were alive and not emigrated by the end of the time period in 
question. Assessment of daily dose of HT was based on recommended dose, 
or designated daily dose (DDD), equaling 182 for a half-year period, i.e. one 
dose per day during half a year.  The DDD’s for transdermal preparations are 
estimated based on the amount of active ingredient delivered per 24 hours and 
the number of days each patch is used. The dose used during each half-year 
period was estimated based on the dose and frequency of dispensing as the 
percentage of the recommended dose dispensed during each half-year period: 
one daily dose for ≥ 135 out of 182 days (≥ 75%), one daily dose for 90 to 134 
out of 182 days (50-75%), one daily dose for 45 to 89 days out of 182 days (25-
50%), one daily dose for less than 45 out of 182 days (< 25%).  
 
We focused on HT use during the period 0.5-1 year after diagnosis, but also 
assessed use during a full one-year period 0.5-1.5 years after diagnosis to 
allow for carry-over effects of dispensing between periods. In addition, we 
assessed use during the entire follow-up period in women considered in need 
of HT.  
 
In study IV the exact dates of sick leave and disability pension were retrieved 
from the Social Insurance database [398]. The net number of lost workdays of 
sick leave or disability pension per year of follow-up was calculated by 
multiplying the number of days with the proportion of compensation received 
[399]. The occurrence of disability pension was also assessed separately 
during follow-up. 
 
Co-variates 
 
In study III, age, FIGO stage, year of diagnosis, and histopathology were taken 
from the Cancer Register. 
 
In study IV data on education level, unemployment occurring in the time period 
1-2 years before diagnosis and family situation at diagnosis or match year was 
taken from the LISA database. From the Social Insurance database MIDAS we 
retrieved information on sick leave occurring in the time period 1-2 years before 
diagnosis (the year prior to diagnosis was not considered due to potential 
association with early cancer symptoms).  
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Follow-up 
In study III the women were followed from cervical cancer diagnosis up to 
maximum 50 years of age (menopausal age), migration, death, or end of the 
study period (April 1st 2011), whichever came first.  
 
In study IV patients and comparators were followed from date of diagnosis or 
match date up to maximum 65 years of age (retirement), migration, death, or 
end of the study period (September 30th 2013), whichever came first. In the 
analysis of relapse-free patients versus comparators, date of cancer relapse 
(as recorded in the NPR) was additionally included as an end of follow-up, and 
patients and participants were censored 3 months before end of follow-up. The 
three-month lag period was used in this analysis to avoid influence of sick leave 
and disability pension related to early symptoms of cancer relapse. 
 
Ethical permission 
The regional ethics board in Stockholm approved both studies (Dnr 2007/1335-
31/4 and 2010/1624-32). 
 
Statistical analyses 
In study III, the Jonckheere-Terpstra test [400, 401] was used to compare 
doses of HT for variables with an assumed a priori ordering, i.e. FIGO stage 
(0,I, II, III-IV) year of diagnosis (2005, 2006, 2007, 2008, 2009) and age (22-29, 
30-34, 35-39, 40-45). The Joncheree-Terpstra test is similar to the Kruskal–
Wallis test in that both tests rely only on the ordering of the outcome, 
however, when there is an a priori ordering also of a predictor, the 
Jonckheere-Terpstra test has more statistical power than the Kruskal–Wallis 
test which assumes unordered groups in the predictor. The Pearson Chi-
squared test [402] was used to examine if doses of HT differed between 
patient groups with different tumor histopathology (adenocarcinoma, 
squamous cell carcinoma, other). 
In study IV, the mean number of lost workdays per year during follow-up after 
diagnosis or match date was assessed among patients and comparators, and 
differences were computed using multivariable linear regression, adjusted for 
age (<30, 30-39, 40-49, 50-60 years), match year (2003, 2004, 2005, 2006, 
2007, 2008, 2009), region (North, Uppsala-Örebro, Stockholm, South-East, 
West, South), education (0-9, 10-12, >12 years), family situation at 
diagnosis/match year (single with children, single without children, couples with 
children, couples without children) and for sick leave (yes/no), disability pension 
(yes/no) and unemployment (yes/no) 1-2 years before diagnosis or match year. 
The variables for adjustment were chosen a priori, based on previous 
knowledge of possible confounding factors [342, 403-407].  
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Linear regression assumes - apart from linearity of the relationship between 
dependent and independent variables - statistical independence of the errors, 
constant variance of the errors and normality of the error distribution, which 
cannot be assumed if the population is unknown. Bootstrapping (coined by 
Efron in 1979) [408], allows estimation of the empirical sampling distribution of 
the data. The basic idea of bootstrapping is to draw inferences about a 
population by resampling the sample data and performing inference on the 
resample. In bootstrap-resamples, the “population” is in fact the sample, and 
this is known; hence the quality of inference from resample data to the “true” 
sample is measurable. Confidence intervals were estimated by taking the 5th 
and 95th empirical percentiles from the bootstrap distribution of the estimated 
parameter. 
 
Cox regression [409], or Cox proportional hazards regression, is a method for 
investigating the effect of several variables upon the time a specified event 
takes to happen. The Cox model estimates the hazard ratio (HR), i.e. the 
relative event rate when comparing two groups over the study follow-up. The 
HR of disability pension was calculated using the Cox regression model and 
patients with disability pension before diagnosis were excluded in those 
analyses. An important assumption is that the effects of the predictor variables 
are constant over the study follow-up. To test if predictor variables are constant 
over time, several methods are available. We used the Grambsch-Therneau 
test of trend in Schoenfeld residuals [410] and found no evidence that the 
proportional hazards assumption was violated. In multivariable analyses of risk 
of disability pension, the Cox model was adjusted for the matching variables 
(age, calendar year, region, education) and for family situation and previous 
unemployment and previous sick leave. Associations of socio-demographic 
factors with risk of disability pension during follow-up among the cervical cancer 
patients were examined by Cox regression with adjustment for the same 
variables. The interaction between sick leave and cancer treatment (effect 
modification) was examined by the likelihood-ratio test. 
 
All statistical tests were 2-sided and p < 0.05 was considered significant. SAS 
(version 9.2 and 9.4, SAS Institute Inc, Cary, NC, USA) and STATA 
(StataCorp, release 12 and 13, College Station, TX,USA) software were used. 
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RESULTS OF STUDY I-IV 
 
STUDY I: AMH after cervical cancer treatments 
 
After radical hysterectomy, pelvic lymphadenectomy and SOE (n = 6) or 
chemoradiotherapy (n = 14), serum levels of AMH were undetectable in all 
women, and 16 of 20 women were on HT. After radical hysterectomy and 
pelvic lymphadenectomy with ovarian preservation (n = 9), mean serum AMH 
decreased by 0.9 ± 0.7 μg/L, from 2.0 ± 1.4, representing a 45% reduction. 
Serum levels of FSH changed from 5.5 ± 1.6 to 5.9 ± 2.9 IU/L and estradiol 
from 204 ± 93 to 228 ± 169 pmol/L (not significant). All women with preserved 
ovaries had serum FSH values < 30 IU/L one year after surgery. 
 
STUDY II: Testosterone and sexual function after treatment 
 
Among women with irradiated ovaries (n = 38), serum levels of FSH and LH 
increased from baseline to one year after radiotherapy with or without 
chemotherapy in both pre- and postmenopausal women and estradiol 
decreased. Simultaneously, the median serum level of total testosterone 
decreased from 0.6 to 0.4 (-29%) in premenopausal women (n=16) and from 
0.7 to 0.5 (-25%) in postmenopausal women (n = 22). Serum levels of free 
testosterone decreased from median 9 to 6 pmol/L (-22%) in premenopausal 
women and from median 8 to 6 pmol/L (-29%) in postmenopausal women. For 
androstenedione, premenopausal, but not postmenopausal, women had a 
median value that was lower one year after radiotherapy, whereas median 
DHEAS was lower at one-year follow-up only among the postmenopausal 
women. 
  
As expected, serum FSH increased among premenopausal women with 
removed ovaries (n = 10) but not among those with preserved ovaries (n = 12). 
In contrast to premenopausal women with irradiated ovaries, serum levels of 
total and free testosterone and androstenedione were not significantly reduced 
among premenopausal women with removed ovaries.  
 
Before treatment, 83% of the women in the irradiated ovaries group and 90% of 
women in the removed ovaries group had FSFI < 26.5, suggestive of sexual 
dysfunction, versus 36% of the women in the preserved ovaries group. Median 
total FSFI-score differed by treatment at baseline and the lowest scores were 
found among women in the irradiated ovaries group. At one-year follow-up, 
total FSFI scores no longer differed by treatment. All groups had a tendency 
towards higher scores at one-year follow-up compared to baseline values, 
although not statistically significantly higher. At one-year follow-up, the 
proportion of women with FSFI < 26.5 was 80% for patients with irradiated 
ovaries, 44% for those with removed ovaries and 40% for those with preserved 
ovaries. Correlations between total and free testosterone, androstenedione and 
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FSFI scores at one year were examined among women with complete FSFI-
questionnaires who had reported being sexually active at baseline (n=39), by 
treatment group. No pattern of correlation was seen.  
 
We compared characteristics of women with FSFI < 26.5 (n=24) to those with 
FSFI ≥ 26.5 (n=15) one year after treatment. The two groups did not differ 
regarding age, partnership status, and sexual function at baseline or use of HT 
or vaginal estrogen. Women with FSFI ≥ 26.5 had lower FSH levels, while other 
hormones, including all androgens, were similar. 
 
STUDY III: HT use after radiotherapy or surgical castration 
 
Among all women classified as “in need of HT”, based on recorded treatment 
(n=257), 46% had dispensing corresponding to 75% or more of recommended 
dose (1 tablet/day for at least 135 of 182 days) during the period 0.5 to 1 year 
after diagnosis. HT doses differed by age: 64% among women aged 22-29 
years versus 33% among women aged 40-45 years dispensed at least 75% of 
full dose. There were no differences in HT doses used by calendar year of 
diagnosis, FIGO stage, or histopathology. 
 
Over the entire follow-up period, the proportion of HT users diminished 
gradually. During the period 4.5 to 5 years after diagnosis 39% of the women 
considered in need of HT and available for follow-up during that period had at 
least one dispensing, and 21% dispensed ≥75% of the recommended dose. 
Among women aged 22 to 39 years at diagnosis, 79% were HT users 0.5 to 1 
year after diagnosis and 56% dispensed ≥75% of recommended dose, 
decreasing to 45% for any use at 4.5 to 5 years, and 21% for ≥75% of 
recommended dose. Among women aged 40 to 45 years, 32% were users at 
the end of follow-up and 21% dispensed ≥75% of recommended dose 
(compared with 50% and 33%, respectively at 0.5 to 1 year). 
 
When HT use was examined for the time period 0.5-1.5 years from diagnosis 
(365 days instead of 182 days) the proportion of users increased from 67 to 
71% but the proportion of women dispensing ≥75% of recommended dose was 
unchanged at 46%.  
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STUDY IV: Work loss among cervical cancer survivors 
 
During the first year following diagnosis, 75% of the cervical cancer patients (n 
= 1971) experienced sick leave or disability pension the whole (365 days) or 
part (< 365 days) of the year, and this was true for 39% during the second year, 
and 32% the third year. Among the comparators (n = 9254) 13-25% had part- 
or full time sick leave or disability pension during follow-up. Overall, cervical 
cancer patients had more lost workdays than comparators up to 8 years 
following diagnosis (first year: mean difference 71 days [95% CI 66-76]; 8th 
year: mean difference 9 days [95% CI 2-16]). When disregarding time after 
relapse, as classified based on relapse and re-treatment codes, relapse-free 
cancer survivors had a higher mean number of lost workdays versus 
comparators up to 4 years following diagnosis (mean difference 4th year: 6 
days [95% CI 1-11], p<0.05). 
 
Mean number of lost workdays during follow-up differed between treatment 
groups, which was partly explained by age differences. Women treated with 
fertility-sparing surgery (median age 33 at diagnosis) had more lost workdays 
than their comparators only during the first year following diagnosis, with similar 
results for relapse-free patients versus comparators. Women treated with 
hysterectomy alone (median age 42 years) had more lost workdays than their 
comparators up to 8 years following diagnosis, and this was true up to 3 years 
among the relapse-free versus comparators. Women treated with surgery plus 
chemo- and/or radiotherapy (median age 42 years) had more lost workdays 
versus their comparators up to 5 years and the relapse-free up to 3 years. 
Women with chemo- and/or radiotherapy as only treatment (median age 50 
years) had more lost workdays for 5 years overall, and for 4 years among the 
relapse-free.  
 
The adjusted HR (aHR) of disability pension during follow-up was 2.4-fold 
increased (95% CI 1.8-3.1) among all cervical cancer patients and 1.9-fold 
increased (95% CI 1.4-2.7) among relapse-free patients versus comparators. 
Relapse-free women treated with hysterectomy (aHR 1.8 [95% CI 1.1-2.8]), 
hysterectomy plus chemo- or radiotherapy (aHR 2.5 [95% CI 1.2-5.4]) or 
chemo- or radiotherapy alone (aHR 3.0 [95%CI 1.3-6.8]) were at increased risk, 
whereas women treated with fertility-sparing surgery were not. 
 
Among the patients only, treatment type and pre-diagnostic sick leave, but not 
education, family type or pre-diagnostic unemployment, were associated with 
risk of disability pension. In particular, women with previous sick leave treated 
with chemo- or radiotherapy (with or without surgery) had an 8-fold risk of 
disability pension compared to women without previous sick leave treated with 
surgery alone. This high risk was present also when only relapse-free patients 
were considered. When testing the interaction between previous sick leave and 
treatment using the likelihood-ratio test, it was significant in the whole group of 
cervical cancer patients, but not among the relapse-free.
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LIMITATIONS 
The choice of study design is typically a trade-off between validity and 
efficiency, and clinical studies are expensive and time consuming. Studies I 
and II are based on a pilot study with limited sample size and statistical 
power. The register-based studies III and IV have the advantage of larger 
materials, but lack detailed information, which may have introduced some 
misclassification, and limited the possibility to control for confounding.  
VALIDITY 
Most systematic errors can be categorized as selection bias, information bias 
or confounding. A systematic error is not dependent on study size and can be 
avoided through a correct study design.  
Selection bias  
Selection bias occurs when the association between the exposure and the 
outcome is different between those who participate and those who do not 
participate in a study. In the clinical cohort that was used in studies I and II, 
the inclusion rate was quite high, but several patients were lost to follow-up, 
or did not complete the questionnaires, giving a response rate for total FSFI 
scores of 48/92 = 52%. We have no reason to believe that the women who 
declined participation or were lost to follow-up had different hormone levels 
than the women who completed the study, but the questionnaire results may 
have been biased. It is possible that women who were lost to follow-up 
differed regarding sexual function to that of those who completed the study. 
Because only women with complete data could be evaluated, this may have 
biased our findings regarding the FSFI questionnaires towards better or worse 
sexual function.   
Papers III-IV have a population-based design, which minimizes selection bias. 
The Swedish Cancer Register has a high overall completeness and for most 
epidemiological use, the underreporting is thought to be without major impact 
[387].  
Information bias 
Information bias can occur if the collected information is incorrect. The 
exposure and outcome can be misclassified in two principally different ways: 
differentially or non-differentially.  
 
Differential misclassification 
 
Differential misclassification may arise when the exposure is misclassified 
unequally in the population, depending on if the individual has the outcome or 
not (and vice versa).  
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In study II, the fact that the women took part in the study and were asked about 
sexuality could in itself have affected the way they responded. The study 
participation could have made the women more attentive of symptoms 
indicating sexual dysfunction, and hence, at one-year follow-up they may have 
reported more distressful symptoms than they would have otherwise. It is also 
possible that bringing up these issues at an early stage reduced the risk of 
future sexual problems and thus lowered the incidence of low sexual function at 
one-year follow-up.  
 
In study IV, disease relapse was based on diagnoses of metastases and re-
treatment codes in the NPR and some underestimation of relapse was 
possible, especially in untreated/very sick patients. However, we believe such 
misclassification to be rare, due to the relatively young age of the study cohort.  
 
We did not have access to the exact retirement dates in study IV, and instead 
patients and comparators were followed until age 65 years. A person that is 
diagnosed with cancer at an age close to retirement may stop working and 
retire early. However, a retired person cannot get sick leave compensation or 
disability pension, and therefore early retirement (before 65 years of age) would 
lead to a reduction in registered work loss days in our cancer population and, if 
anything, an attenuation of the true risks compared with the population. Hence, 
this possible bias cannot explain the increased risks of sick leave and disability 
pension that we observed. 
Non-differential misclassification 
Non-differential misclassification typically occurs when the measurement error 
of exposure or outcome is unrelated to the other factor of interest. Such bias 
arises from misclassification of the exposure or outcome that is similarly 
distributed in the study population. Such error is usually of minor concern in 
epidemiological studies, since it does not shift risk estimates, but only dilutes 
the estimates towards a null result (although there are exceptions to this rule 
[411]). Positive associations are therefore most often not explained by non-
differential misclassification. However, important associations can be 
concealed by non-differential misclassification, and therefore, depending on 
the research question, this could also represent a serious limitation. 
Within and between assay variation regarding the results of the hormonal 
analyses in study I-II is a potential source of error. Different assays are not 
comparable, and therefore all analyses for each hormone were performed in 
batch. The fact that blood-samples were not taken at a specific time of day 
and menstrual cycle day could have affected the hormone results [79, 412, 
413]. It was not possible to standardize blood sampling for practical reasons. 
However, generally serum AMH has been reported to have low intra-cycle 
variation [95]. Serum testosterone, however, has quite large menstrual [413] 
and diurnal [79] variation, at least in women of fertile age, which thus affected 
the results from study II, giving a wider distribution of hormone values, and 
limiting precision. 
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The evaluation of sexual function in study II was limited to the past 4 weeks at 
one-year follow-up, thus assessing a point prevalence of sexual function, but 
for baseline sexual function the women were asked to evaluate function before 
start of cancer symptoms. The baseline questionnaires could have been 
affected by bias due to imprecise recollection, or be negatively affected by the 
recent cancer diagnosis. The FSFI-scores were low at baseline, which 
indicates that perhaps the women did not answer the questionnaires as 
instructed, but rather described their current situation. To allow comparison on 
a fuller data set, missing data from the FSFI questionnaire were imputed using 
means from the same domain. Imputed data can be inaccurate, but since only 
one item per domain was allowed to be imputed, it is improbable that this has 
affected the findings in any major way.  
The scoring of the FSFI can be problematic, because 15 of the 19 items of the 
FSFI give a score of zero for “No sexual activity” or “Did not attempt 
intercourse.” Thus, the scoring system misclassifies sexually inactive women 
as having low sexual function [414, 415]. A woman may have a variety of 
reasons other than low sexual function that explain a 4-week period without 
sexual activity or intercourse. Only the two questions that make up the desire 
domain and two of the three questions that make up the satisfaction domain 
provide answers that are independent of the occurrence of sexual activity. 
Also, one question cannot be answered if a woman does not have a partner. 
This problem is usually addressed by restricting study inclusion to women 
who report sexual activity over the 4-week time period, as we did in our study.  
The NRP that was used in study III and IV to classify the cancer treatment of 
each individual was originally designed to collect data on health care use, but 
is today also a source for management and financing. Financial incitements 
may influence diagnostic coding routines, which probably changes 
epidemiologic patterns over time and also can lead to differences in coding 
patterns between hospitals [390]. 
The validity of the NPR with regard to cervical cancer treatments has not been 
examined, but for other surgical procedures it has a high sensitivity when 
comparing to national quality registers [416], and high positive predictive values 
when comparing to medical records, i.e. patient charts [417, 418]. The validity 
of the register as a whole is regarded high and the validity is thought to be 
higher in patients with severe disease (such as cancer) as opposed to mild 
disease [390]. However, in study III, it is possible that some cancer treatments 
were not recorded in the NPR and that the number of patients receiving 
castrating treatment was underestimated. However, since the use of HT was 
lower in all other treatment groups (including those with missing treatment 
information), it is unlikely that we have underestimated the true prevalence of 
HT among patients with treatment-induced early menopause based on 
misclassification of cancer treatment. It is also possible that some women could 
have contraindications to HT unknown to us. However, it is unlikely that this 
would apply to all 33% of the women deprived of endogenous estrogen with no 
dispensing.  
  
	   Limitations	   	  	   	  
71 
In study IV, only sick leave episodes >14 days were recorded in the register, 
and therefore the mean number of lost workdays is an underestimation of the 
total burden of sick leave. This, however, also applied to the comparators and 
should therefore not affect the observed differences. Disability pension, the 
main reason for long-term work absence, was registered from the first day. It 
is also possible that cervical cancer patients had more short-term sick leave 
than the comparators, something we were unable to discover, since these 
short-term sick leave episodes were not recorded in the database. 
Confounding  
Confounding is of central importance in any epidemiologic study; it refers to 
the mixing of effects. The definition of a confounding factor states that it 
needs to be associated with both the exposure and the outcome, but not 
constitute an intermediate link in the causal chain of events. Confounding can 
cause an over-, or underestimation of an effect. Provided that the 
measurement of a potential confounding factor is accurate, confounding can 
be controlled for in the study design by restriction or matching, or in the data 
analysis through adjustments in the regression model or by stratification.  
In study II, the potential association between declining serum testosterone and 
impaired sexual function may be subject to confounding by age and treatment. 
Serum androgen levels decline by age, and so does sexual activity and sexual 
function [235, 236]. However, declining androgen levels may also be seen as a 
link in the causal chain between increasing age and decreasing sexual 
function, and should in this case not be seen as a confounder. The same is 
true for cancer treatment. The treatment that causes androgen levels to decline 
can in itself cause sexual dysfunction. Even if an association between, for 
instance, radiotherapy and decreased androgen levels and low sexual function 
were established, the impact of other treatment effects are hard to distinguish 
from the effect of declining androgens levels. In order to adjust for treatment in 
the correlation tests, FSFI-scores and androgen levels were compared for each 
treatment group separately.  
 
A large number of factors are thought to influence sexual function in women, 
such as physical conditions, mental disorders, lifestyle and socio-economic 
factors, previous experiences, and cultural and religious beliefs [419].  In order 
to adjust fully for all other potential confounders, we would have needed a 
much larger material, and therefore we chose the more straightforward method 
of direct correlation, instead of an adjusted multivariable model, in this pilot 
setting.  
 
In study IV, confounding from socio-demographic factors and changes in 
economic benefits over time was reduced by the use of age-, period-, region- 
and education-matched population comparators. Some residual confounding is 
possible, since we did not have information on covariates associated with work 
loss, such as smoking [420], job strain [349], social climate at work [347], and 
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other economic factors, such as income levels [421]. However, the impact of 
the latter should be relatively small since sick leave levels before 
diagnosis/match date were similar among patients and comparators.  
 
External validity  
Provided that the results reported in this thesis are not subject to any major 
biases (threats to the internal validity), the findings could be valid for 
populations beyond Sweden. The results from study I may not be applicable 
to populations of other ethnicities since some ethnic variation in AMH has 
been reported [380]. Also, in study II, the generalizability of our results on 
sexual function is limited to women in similar circumstances (such as age, 
partnership status, cancer treatment etc.).  
In study III, women’s use of HT can be affected by the cost of the medication. 
The Swedish healthcare system offered prescription drugs free of charge 
above an annual threshold of SEK 1,800 during the study period. A higher 
cost may in other countries reduce HT use even further.   
Regarding the generalizability of study IV, social systems differ between 
countries regarding insurance systems for the employed, self-employed and 
unemployed, the maximum duration of sick leave and the amount of benefit 
received [343]. In comparison to many other countries, Sweden has generous 
and comprehensive social security and therefore, our results may not be 
generalizable to other countries in absolute terms. However, the system was 
the same for patients and comparators and therefore observed differences 
between cancer patients and comparators could be generalizable. 
 
PRECISION 
Random error is the error that remains when systematic errors have been 
eliminated. The risk of random errors can be decreased with an increase in 
sample size. The role of chance can be reflected statistically by p-values or 
the width of confidence intervals. A hypothesis test of an analysis is based on 
the null hypothesis, which states that there is no relation between the 
exposure and outcome, and the result is statistically significant if the observed 
data deviates sufficiently from the null hypothesis, i.e. p < 0.05 and the null 
hypothesis is rejected. A p ≥ 0.05 indicates that the null hypothesis cannot be 
rejected. If the null hypothesis is falsely rejected, a type 1 error has occurred, 
meaning that a difference is suggested when there truly is none. A type 2 
error would occur if the null hypothesis fails to be rejected although it should, 
meaning that there is a difference but we have failed to identify it.  
Sample size is a limitation in studies I and II. Our finding of a reduction in 
serum AMH and testosterone could be afflicted by type I error, i.e. there 
actually was no difference. A comparison group would have strengthened the 
results. In study II, we found no association between testosterone levels and 
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sexual function, which could be due to lack of power, i.e. a type II error. The 
reduction in serum testosterone after SOE was similar to the reduction after 
radiotherapy, but was not statistically significant, which could be due to smaller 
number of patients in that treatment group.  
 
In register-based cohort studies such as in studies III-IV, the large size of the 
studied cohorts enhances precision and allows for more stable risk estimation. 
However, chance can never be excluded as a potential explanation for 
observed results. In some of our subgroup-analyses, sample size was reduced 
and the confidence intervals were wide, which makes the specific risk 
assessment uncertain for these groups.
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        FINDINGS AND IMPLICATIONS 
STUDY I: AMH after cervical cancer treatments 
 
The main finding in study I was that radical hysterectomy and pelvic 
lymphadenectomy with ovarian preservation was associated with a 45% 
decline in mean serum levels of AMH one year after treatment, but with no 
changes in serum levels of FSH and estradiol. The fact that AMH 
concentrations fell to undetectable levels after chemoradiotherapy and SOE 
was expected. However, the decline in AMH following radical hysterectomy 
implies that the surgery affected the women’s ovarian function, even though the 
ovaries were not removed. The women in our cohort had AMH concentrations 
that could have started to decline more rapidly due to imminent menopause. 
However, in the general population, mean AMH reduction per year among 
women of reproductive ages has been reported to be 0.16 µg/L [422] or 5.6% 
[423], which is less than the 0.9 µg/L decline in AMH found in our study. Still, 
the sample size of our pilot study was limited, and our suggestive finding could 
be followed up in larger studies, and ideally include a comparison group. 
 
The decline in serum AMH observed in this study has potential implications for 
reproduction as well as for menopausal state. The only possibility in clinical 
practice for a woman to have a biological child after hysterectomy is in vitro 
fertilization (IVF) and a gestational carrier/surrogate mother. This procedure is 
not allowed in Sweden, but internationally successful pregnancy outcomes 
have been described for patients with cervical cancer, also after ovarian 
transposition and chemoradiotherapy [424, 425]. Recently, uterus 
transplantation has emerged as a new possibility for women with absolute 
uterine factor infertility, and has been performed on one hysterectomised 
woman with previous cervical cancer [426]. The first case of a live birth after 
uterus transplantation was described in 2015 [427]. AMH levels can in such 
cases predict future ability to stimulate the ovaries with gonadotropins to 
acquire eggs for IVF [97].  
The other potential importance regarding the decline in serum AMH is that it 
could indicate a risk of early menopause. Menopause occurs at a median age 
of about 51 years, dictated by the decline in the number of follicles in the 
ovaries (the ovarian reserve) with increasing age. Using age and AMH, the 
age range in which menopause will subsequently occur can be individually 
calculated. Different models for predicting time to menopause have been 
developed. In the model by Tehrani et al. [100], age alone had an adequacy 
of 84% to predict age at menopause correctly, which rose to 92% when AMH 
was added to the model. An AMH value of 2.0 µg/L in a woman of 30 years 
predicted a menopausal age of 52 (but with large CI: 42–57), whereas an 
AMH value of 1.1 µg/L predicted age of menopause to 45 (37–50). In 
Freeman et al. a decline from 2.0 to 1.1 µg/L would, in the case of a woman 
40-44 years of age, imply a reduction of time to menopause of 2.5 years. 
Women undergoing radical hysterectomy could benefit from assessing their 
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estimated time to menopause to ensure adequate hormone supplementation 
in such cases. As these women no longer menstruate, the onset of 
menopause may go unnoticed.  
 
STUDY II: Testosterone and sexual function after treatment  
 
Study II showed that levels of total and free testosterone decreased slightly 
after pelvic radiotherapy treatment for cervical cancer among pre- as well as 
postmenopausal women. Among premenopausal women treated with surgery 
with SOE, the decline in serum androgen concentrations did not reach 
statistical significance, maybe due to a smaller number of patients in that 
group. No direct correlation was found between androgen levels and FSFI 
scores of sexual function one year after treatment, in line with previous studies 
on breast cancer patients [158, 163, 164]. However, women with low sexual 
function at one-year follow-up had higher FSH levels. Serum levels of FSH 
reflect estradiol levels, and endogenous estradiol levels have been shown to 
correlate with sexual function in postmenopausal women [428].  
 
Testosterone production declines naturally by age [119] and, theoretically, part 
of the reduction in serum testosterone observed in this study could be due to 
the natural effect of ageing. However, the expected age-dependent decline in 
serum testosterone levels after one year is much smaller than that 
demonstrated after radiotherapy [429]. 
 
The importance of the slight reduction of total and free testosterone after 
radiotherapy observed in this study is not clear. No single androgen level was 
predictive of low female sexual function in a large study performed in a healthy 
non-cancer population [128]. Also in our study, androgen levels were not found 
to be directly associated with sexual function, but our limited sample size 
makes the findings uncertain. Our results do not support the hypothesis that 
serum testosterone values reflect sexual function in cervical cancer survivors, 
though it cannot be ruled out as a possibility, since we did not have statistical 
power to adequately examine this association. However, circulating 
testosterone levels do not necessarily reflect concentrations in target cells.  
Testosterone may act as a paracrine and intracrine hormone, rather than as a 
classic hormone [78].  
 
Female sexual dysfunction consists of a continuum of psychosexual disorders 
and HSDD interrelates with problems of arousal, orgasm, and sexual pain 
[430]. Many other factors may better predict sexual function in our cohort, such 
as relationship quality, sequelae of treatment, other chronic illnesses and drugs 
[430]. A cancer diagnosis can cause increased relationship strain, and studies 
have shown that cervical cancer survivors are at increased risk of divorce [431, 
432].  
 
Many women in our study had higher FSFI scores one year after treatment, 
contrary to what could be expected. The explanation could be that the women 
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were affected by their recent cancer diagnosis at baseline, and did not answer 
the questionnaire as instructed, i.e. according to experiences before start of 
cancer symptoms. It is also possible that a cancer diagnosis changes priorities 
and attitudes to life and that cancer survivors can experience a revitalization 
and positive change of their sexual life and behavior.   
Among all women in study II, including the sexually inactive, the lowest FSFI 
values were found among women who were older and single. Low FSFI 
scores were also found among women with more advanced tumors. Since 
coital bleeding is an early symptom of cervical cancer, sexually inactive 
women are more likely to discover their tumors at more advanced stages. 
 
STUDY III: HT use after radiotherapy or surgical castration  
 
The main finding in study III was that less than half of the women likely in early 
menopause due to cervical cancer treatment dispensed HT at a recommended 
dose or close (≥ 75%). Younger women (< 40 years) had a higher prevalence 
of HT use compared to women aged 40-45 years, but HT use decreased over 
time in both groups. The higher prevalence of HT use in younger age groups 
could reflect more severe menopausal symptoms, and thus a more obvious 
need for treatment. We did not observe any differences in the prevalence or 
doses of HT among women treated for cervical adenocarcinoma compared 
with those treated for squamous cell carcinoma, which was unexpected, since 
HT use after cervical adenocarcinoma has been debated [433].  
 
Our findings of low HT use among women in early menopause have been 
confirmed in a recent study on HT use among all Swedish women aged 40-44 
[434]. Less than 1% dispensed HT, and the occurrence of spontaneous early 
menopause is expected to be around 5%. A majority of those women 
dispensed HT less than a year.  
 
Even though the use of HT dispensing as a measure of exposure eliminates 
bias due to bad recollection and may improve the accuracy of the information 
on HT use [435], we do not know whether the women used the dispensed 
medication. Patient adherence to medication in general has been reported to 
be around 50% [436], but with large variations [437, 438]. Therefore, we 
cannot exclude that the actual use was lower than that estimated.  
 
We do not know why patients in this study did not use or stopped using HT - if it 
was because of the patients’ own choice or if they were advised to do so by 
their physician. Treatment guidelines on cervical cancer seldom address the 
question of HT, which makes the decision to prescribe HT much up to the 
discretion of the individual gynecologist or oncologist. Our results call for 
increased awareness among professionals and women of the health benefits of 
HT up to the age of natural menopause and the lack of evidence for adverse 
effects of HT in this young patient group.  
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STUDY IV: Work loss among cervical cancer survivors 
 
Cervical cancer patients had on average more lost workdays than comparators 
for 8 years following diagnosis, and relapse-free patients had more lost 
workdays for 4 years versus comparators. We therefore conclude that part – 
but not all – of the work loss in the cohort was explained by cancer progression 
or relapse. The long-standing increase in number of lost workdays, and an 
increased risk of disability pension, was evident among relapse-free patients 
treated with hysterectomy or chemo/radiotherapy. However, it is also important 
to point out that the majority of the patients had no registered days on sick 
leave or disability pension from the second year after treatment and onwards. 
Also, early-stage patients treated with fertility-sparing surgery had no excess 
risk, except during the year of diagnosis and treatment.  
As in studies of cancer patients in general [343, 344] as well as in 
gynecological cancer patients [356], our study showed that the majority of the 
patients did not experience any excess work loss beyond the first year, 
although the group as a whole had more lost workdays for several years. 
However, 6% of the patients received disability pension during follow-up, 
compared to 3% among the comparators. Disability pension in Sweden is a 
risk factor for increased mortality compared with non-retired persons, even 
after adjustment for socio-economic factors and underlying disease [439]. 
Disability pension was 4-6 times higher among patients with previous sick 
leave (which can be seen as a proxy for co-morbidity not associated with the 
cancer diagnosis) compared to patients without previous sick leave, and the 
highest risk was found among patients with previous sick leave and 
chemo/radiotherapy, thus delineating a high-risk group. Other socio-
demographic factors were not associated with disability pension in our study. 
We do not know the exact reasons for the increased sick leave and disability 
pension among relapse-free patients found in this study, but we know from 
previous studies that cervical cancer survivors experience a plethora of 
distressful symptoms after treatment. The fact that women with limited 
treatment had no excess work loss indicates that treatment side effects could 
explain some of the excess lost workdays.  
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CONCLUSIONS 
 
• Serum AMH fell to undetectable values after radiotherapy or SOE, as 
expected. Radical hysterectomy was associated with a decline in AMH 
one year after surgery, but the sample size was small (n=9) (Study I).  
 
• Testosterone levels in serum declined after radiotherapy. No association 
was suggested between serum testosterone levels and sexual function 
scores at one-year follow-up (Study II). 
 
• Less than half of women in early menopause due to SOE or 
radiotherapy following cervical cancer diagnosis dispensed HT at a 
recommended dose or close (Study III). 
 
• Women treated with hysterectomy or chemo/radiotherapy – but not 
women treated with fertility sparing surgery – had an increased risk of 
sick leave and disability pension several years after treatment, which 
was only partly explained by cancer progression or relapse (Study IV). 
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FUTURE RESEARCH 
• Fertility preservation for cancer patients depends on determination of 
risk of fertility impairment by treatment, and an estimate of the length of 
the remaining reproductive window after treatment. Better prediction 
models need to be developed for this outcome, where serum AMH is 
one promising marker that can be used. Also, new techniques for 
fertility preservation, such as in vitro maturation of immature oocytes 
retrieved in unstimulated cycles, pharmacological protection of ovaries 
during chemotherapy, cryopreservation of ovarian cortical tissue and 
primordial follicle isolation need to be developed further.  
 
• Sexual dysfunction and other distressful symptoms are common after 
cancer treatment. Minimally-invasive, nerve-sparing surgery as well as 
sentinel node biopsy for lymph nodal staging may reduce the risk of 
such complications. More studies are needed to evaluate new surgical 
techniques.  
 
• Predictors for not using HT following treatment-induced early or 
premature menopause among cervical cancer patients could be 
evaluated, in order to improve adherence to medication. 
 
• The morbidity and attitudes behind increased sick leave and disability 
pension among relapse-free patients need to be identified, in order to 
develop interventions to improve vocational rehabilitation.  
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SAMMANFATTNING PÅ SVENSKA 
Livmoderhalscancer drabbar kvinnor i alla åldrar och ungefär hälften är under 
50 år vid diagnos. Eftersom de flesta blir botade, kommer många kvinnor att 
leva länge med konsekvenserna av sjukdomen och dess behandling. 
Livmoderhalscancer kan behandlas genom att operera bort livmodern, och 
ibland också äggstockarna, samt med strålbehandling och cellgifter. Om 
tumören är liten kan det ibland räcka med att bara ta bort en bit av 
livmoderhalsen, s.k. cervixamputation eller trachelektomi, och då kan kvinnan 
fortfarande bli gravid och få barn. Yngre kvinnor som genomgår 
strålbehandling, eller där äggstockarna opereras bort, hamnar omedelbart i 
klimakteriet. Om kvinnan är under 50 år vid cancerbehandlingen 
rekommenderas sedan östrogenbehandling upp till minst 50 års ålder mot 
klimakteriebesvär och för att minska risken för hjärt-kärlsjukdom och 
benskörhet. Efter behandling mot livmoderhalscancer är det vanligt att 
kvinnorna får symtom från tarm och urinblåsa, bensvullnad och sexuella 
problem.  
 
Syften med avhandlingen var att undersöka hur hormonnivåer i blodet 
påverkas av cancerbehandling, om yngre kvinnor som hamnar i klimakteriet 
p.g.a. behandlingen använder östrogen, samt och i hur hög utsträckning 
kvinnor som haft livmoderhalscancer är sjukskrivna jämfört med befolkningen. 
 
Studie I: Anti-Müllerskt hormon (AMH) utsöndras från äggstockarna och kan 
mätas i blod. Nivån av AMH tros kunna förutsäga ungefär om hur lång tid 
kvinnan kommer att hamna i klimakteriet. Vi mätte AMH i blodet hos 29 kvinnor 
under 45 år före och efter olika behandlingar för livmoderhalscancer. Vi fann att 
nivåerna blev omätbara om kvinnan fått strålbehandling eller opererat bort 
äggstockarna. Om livmodern opererats bort men äggstockarna lämnats kvar, 
minskade AMH med nästan hälften, vilket skulle kunna innebära en risk att 
kvinnan hamnar i klimakteriet tidigare än hon annars skulle ha gjort. 
 
Studie II: Testosteron tror man har betydelse för allmänt välbefinnande och 
sexualitet hos kvinnor, men man vet inte hur testosteronnivåer i blodet 
påverkas av behandling för livmoderhalscancer. Man vet inte heller om 
sexuella besvär efter behandling kan bero på låga testosteronnivåer. Vi mätte 
testosteron i blod hos 60 kvinnor i alla åldrar före och efter olika behandlingar 
för livmoderhalscancer, och kvinnorna fick samtidigt fylla i formulär angående 
sexuella besvär. Vi fann att testosteron minskade efter strålbehandling. 
Däremot kunde vi inte hitta några samband mellan testosteronnivåer och 
sexualitet. 
 
Studie III. Vi sammanställde information från Cancerregistret, Patientregistret 
och Läkemedelsregistret på uthämtade recept på läkemedel med östrogen 
bland kvinnor under 45 år som haft livmoderhalscancer och som behandlats 
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med strålning eller borttagande av äggstockarna. Vi fann att mindre än hälften 
av kvinnorna använde östrogen i rekommenderad dos, eller minst tre 
fjärdedelar av full dos, under det första halvåret efter behandlingen. Många 
slutade också använda östrogen under de närmast följande åren. Det kan 
innebära en risk att dessa kvinnor senare drabbas av hjärt-kärlsjukdom och 
benskörhet. Både kvinnor och läkare kan behöva informeras om att 
östrogenanvändning före 50 års ålder rekommenderas och bedöms vara 
fördelaktig för dessa kvinnor. 
  
Studie IV: Vi sammanställde information från Cancerregistret, Patientregistret 
och Försäkringskassan om sjukskrivning och förtidspension bland kvinnor som 
haft livmoderhalscancer, och jämförde med en kontrollgrupp kvinnor som inte 
haft livmoderhalscancer men som hade motsvarande ålder, utbildning, 
uppföljningstid och bodde i samma sjukvårdsregion. Vi fann att kvinnor som 
haft livmoderhalscancer, och inte hade några tecken på återfall i registren, 
hade mer sjukskrivning och förtidspension under de 4 första åren efter sin 
sjukdom. Risken för förtidspension var större hos alla kvinnor som behandlats 
för livmoderhalscancer, förutom för dem, som endast genomgått mindre kirurgi 
(d.v.s. enbart operation av livmodertappen). Den ökade sjukfrånvaron bland 
kvinnor som haft livmoderhalscancer kan bero på biverkningar av 
behandlingen, även om andra orsaker kan gälla för enskilda kvinnor i studien.
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APPENDIX 
 
Codes used for classification of cervical cancer treatment. 
 
Cervical cancer treatment NOMESCO/KKÅ/KVÅ/CD10 codes 
Study III  
 Cervical resection LDC00, LDC03, LDC10, LDC96 
 Hysterectomy LCD00, LCD01, LCD 04, LCD 10, LCD 11, LCD 30, 
LCD 31, LCD 40, LCD 96, LCD 97 
 Unilateral oophorectomy/SOE LAF00, LAF01, LAE10, LAE11 
 Bilateral oophorectomy/SOE LAF10, LAF11, LAF20, LAE20, LAE21 
 Pelvic lymphadenectomy PJD55, PJD45 
 Radiotherapy Z510, Z08.1, Z92.3, Z08.7, DV013-DV018 
 Chemotherapy DT107, DT108, DT116, Z511, Z512 
 Trachelectomy LDC00, LDC03, LDC10, LDC96 in combination with 
PJD55, PJD45 
Study IV  
 Hysterectomy 
 
LCD00, LCD10, LCD30, LCD11, LCD01, LCD31, 
LCD96, LCD04, LCD40, LEF13 
 Cervical resection/conisation LDC10, LDC03, LDC96, LDC00, LDB00, LDW96 
 Pelvic exenteration LCE00, LCE10, LCE20, LCE96 
 Radiotherapy/ Follow-up examination  ZV031, ZV033, DV012-DV018, DV070, DV071, 
Z510/Z081, Z923 
 Chemotherapy/ Follow-up examination  DT107, DT108, DT116, Z511/Z082 
 Follow-up examination after combined 
treatment  
Z087 
 Secondary malignant tumor  C77, C78, C79 
 
SOE=salpingo-oophorectomy 
 
